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Interleukin-1 (IL-1) is a central mediator of innate immunity and inflammation. The IL-1 family includes seven
ligands with agonist activity (IL-1a and IL-1b, IL-18, IL-33, IL-36a, IL-36b, IL-36g), three receptor antagonists
(IL-1Ra, IL-36Ra, IL-38), and an anti-inflammatory cytokine (IL-37). Members of the IL-1 Receptor (IL-1R) fam-
ily include six receptor chains forming four signaling receptor complexes, two decoy receptors (IL-1R2,
IL-18BP), and two negative regulators (TIR8 or SIGIRR, IL-1RAcPb). A tight regulation via receptor antago-
nists, decoy receptors, and signaling inhibitors ensures a balance between amplification of innate immunity
and uncontrolled inflammation. All cells of the innate immune system express and/or are affected by IL-1 fam-
ily members. Moreover, IL-1 family members play a key role in the differentiation and function of polarized
innate and adaptive lymphoid cells. Here we will review the key properties of IL-1 family members, with
emphasis on pathways of negative regulation and orchestration of innate and adaptive immunity.Introduction
Interleukin-1 (IL-1) was the first interleukin to be identified (for
recent review, Dinarello, 2009, 2010; Dinarello et al., 2012;
Gabay et al., 2010; Sims and Smith, 2010) and has served as
a groundbreaking molecule with implications extending far
beyond its extended family. The original description of a cytokine
acting at vanishingly low concentrations on cells and organs as
diverse as the hypothalamus and T lymphocytes was without
precedent in biology (for review, Dinarello, 2009): pleiotropism
turned out to be a common property among cytokines. Early
on, it was realized that IL-1 was responsible for resistance
against microbes (van der Meer et al., 1988), a discovery up-
stream of the identification of the TIR domain (originally standing
for Toll-IL-1 resistance; shared by the IL-1 receptor [IL-1R] and
Toll-like receptors [TLR]), and of the inflammasome. Along the
same line, the function of MyD88 as a key adaptor was first
discovered for IL-1R and then extended to TLR (Muzio et al.,
1997, 1998; Sims and Smith, 2010). The IL-1R2 receptor was
identified as a decoy for IL-1 (Colotta et al., 1993), a paradigm
shift since the original definition of ‘‘receptor’’ by Langley in the
19th century (Langley, 1906). Decoy receptors have since
emerged as a general strategy conserved in evolution to limit
the action of cytokines, chemokines, and growth factors. Thus,
IL-1 has served as a forerunner for intercellular molecules and
paradigms, which have had a broad impact in immunology and
medicine at large.
The IL-1 and IL-1R families have grown impressively in size,
complexity, and division of labor (Dinarello et al., 2010, 2012;
Dinarello, 2009, 2010;Gabay et al., 2010). The discovery of innate
lymphoid cells and the dissection of pathways of T cell differenti-
ation have revealed essential functions for IL-1, IL-18, and IL-33
and have opened vistas on their functions (O’Shea and Paul,
2010; Spits et al., 2013). No less important have been the clinical
implications of IL-1 research. Autoinflammatory diseases are
uniquely IL-1-mediated disorders and anti-IL-1 therapies have
had a tremendous impact on inflammatory diseases (Dinarello,2010; Dinarello et al., 2012). Here we will review the common
characteristics of IL-1 family members and specific receptors.
Emphasis will be on the immunobiology of IL-1, its relatives and
their receptors with a focus on selected cytokines (e.g., IL-33,
IL-18, IL-36), pathways of negative regulation, orchestration of
innate and adaptive lymphoid cells, and clinical implications.
An Overview of IL-1 and IL-1R Family Members
As shown in Figures 1A and B and Table 1, IL-1 family ligands
include seven molecules with agonist activity (IL-1a, IL-1b, IL-
18, IL-33, IL-36a, IL-36b, and IL-36g), three receptor antagonists
(IL-1Ra, IL-36Ra, and IL-38), and an anti-inflammatory cytokine
(IL-37). The IL-1R family members include 11 molecules. A
simplified nomenclature for IL-1R members is proposed here:
IL-1R1 (IL-1RI), IL-1R2 (IL-1RII), IL-1R3 (IL-1RAcP), IL-1R4
(ST2), IL-1R5 (IL-18Ra), IL-1R6 (IL-1Rrp2, IL-36R), IL-1R7 (IL-
18Rb), IL-1R8 (TIR8, also known as SIGIRR), IL-1R9 (TIGIRR-
2), IL-1R10 (TIGIRR-1).
The receptor chains are generally characterizedbyanextracel-
lular portion consistingof three immunoglobulin (Ig)-like domains.
Notable exceptions are the IL-18 binding protein (IL-18BP) and
TIR8, which have a single Ig domain. The intracellular portions
are characterized by a TIR domain essential for signaling via the
MyD88 adaptor. The canonical TIR domain present in signaling
receptors of the IL-1 family is sharedbyTLR.Asdiscussedbelow,
at least IL-1a and possibly IL-33 are preformed and released
upon tissue damage, acting as bona fide alarmins. Thus, the
TIR domain is a key transducer in sensing of microbes, tissue
damage, driving amplification of innate immunity, and inflamma-
tion. IL-1R signaling will not be reviewed here and the reader is
referred to Sims and Smith, 2010. Four signaling receptor com-
plexes are formed: the IL-1 receptor (IL-1R1 and IL-1RAcP), the
IL-33 receptor (ST2 and IL-1RAcP), the IL-18 receptor (IL-18Ra
and IL-18Rb), and the IL-36 receptor (IL-1Rrp2 and IL-1RAcP).
Two members of the family are decoy receptors (IL-R2 and
IL-18BP). TIR8 has no ligand and acts as a negative regulator.Immunity 39, December 12, 2013 ª2013 Elsevier Inc. 1003
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Figure 1. Ligands and Receptors in the IL-1
Family
(A) A schematic representation of ligands and re-
ceptor chains in the IL-1 family. The minus sign in-
dicates inhibition. TIR8 (also known as SIGIRR) has
two aminoacid substitutions (Cys222 and Leu305
for canonical Ser447 and Tyr536).
(B) Subfamilies among IL-1 ligands, divided based
on the length of the N-terminal prodomain. Numbers
refer to aminoacids. The cleavage site (N) is located
9 amino acids N-terminal to AXD, a conservedmotif,
where A is an aliphatic amino acid. IL-37 has been
identified only in humans.
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IL-1 affects virtually all cells and organs and is a major patho-
genic mediator of autoinflammatory, autoimmune, infectious,
and degenerative diseases (Dinarello, 2009, 2010; Dinarello
et al., 2012; Gabay et al., 2010; Sims and Smith, 2010) (Table 2).
Here we will summarize functions related to immunity and then
focus on selected aspects (e.g., why there are two IL-1s; role
of IL-1 in cancer and metabolism). Figure 2A highlights actions
of IL-1 that are directly related to immunity. The effects of IL-1
on the central nervous system include fever (IL-1 is the classic
endogenous pyrogen [Dinarello, 2009, 2010; Sims and Smith,
2010]) and activation of the hypothalamus-pituitary-adrenal
(HPA) axis. At elevated temperature, leukocyte migration is
increased. Cortisol downstream of the HPA axis has a regulatory
function on innate immunity and inflammation. The general sig-
nificance of the acute phase response, triggered via IL-6 in the
liver, is to amplify innate resistance mediated by the humoral
arm of innate immunity (e.g., C-reactive protein [CRP]; mannose
binding lectin; complement components) and to regulate tissue
damage (e.g., a1-antitrypsin). Induction of adhesion molecules1004 Immunity 39, December 12, 2013 ª2013 Elsevier Inc.in endothelial cells and chemokines results
in amplification of leukocyte recruitment
and innate resistance to infection. IL-1
markedly prolongs the lifespan and stimu-
lates the effector function of neutrophils
and macrophages (Mantovani et al.,
2011). In addition, IL-1 orchestrates the
differentiation and function of innate and
adaptive lymphoid cells (see below).
IL-1a and IL-1b are encoded by distinct
genes, bind to the same receptor (IL-1R1),
and have similar biological properties.
However, distinctions do exist and impact
on immunity, inflammation, and cancer.
The IL-1a precursor is constitutively
present in epithelial layers of the entire
gastrointestinal tract, lung, liver, kidney,
endothelial cells, and astrocytes. Upon
cell death by necrosis, as occurs in
ischemic diseases such as myocardial
infarction, stroke, acute renal failure, and
tumor necrosis, the IL-1a precursor is
released. Unlike the IL-1b precursor, the
IL-1a precursor is fully active and functions
as an ‘‘alarmin’’ by rapidly initiating acascade of inflammatory cytokines and chemokines, which ac-
counts for sterile inflammation (Chen et al., 2007; Rider et al.,
2011). Thus, IL-1amediates the early phases of sterile inflamma-
tion. Inaddition to the IL-1aprecursor released fromnecroticcells,
there is a membrane form of IL-1a present on activated mono-
cytes. However, circulating IL-1a is rarely detected even in per-
sons with severe infections but is contained in apoptotic bodies
released from endothelial cells (Berda-Haddad et al., 2011).
In contrast, IL-1b is produced by hematopoietic cells such as
blood monocytes, tissue macrophages, skin dendritic cells, and
brain microglia in response TLR, activated complement compo-
nents, other cytokines (such as TNF-a), and IL-1 itself (Dinarello,
2011). Unlike the IL-1a precursor, the IL-1b precursor is not
active but is cleaved by caspase-1, releasing the active cytokine
into the extracellular space. Although caspase-1 is abundant in
hematopoietic cells, the proenzyme (procaspase-1) first requires
cleavage by the inflammasome. The key component of this
macromolecular complex is the protein-nucleotide-binding
domain and leucine-rich repeat pyrin-containing protein-3
(NLRP3) (Hoffman et al., 2001), also called cryopyrin. Single
Table 1. Nomenclature and Main Functions of IL-1 Family Members
Cytokine Alternative Name Receptor Coreceptor
Proposed Nomenclature:
ActivityReceptor Coreceptor
IL-1a IL-1F1 IL-1R1 IL-1R2 IL-1RAcP IL-1R3 Alarmin, inflammation, Th17 cell responses
IL-1b IL-1F2 IL-1R1 IL-1R2 IL-1RAcP IL-1R3 Antimicrobial resistance, inflammation,
Th17 cell responses
IL-1Ra IL-1F3 IL-1R1 Inhibition of inflammation
IL-18 IL-1F4 IL-18Ra IL-18Rb IL-1R5 IL-1R7 Inflammation, Th1 cell responses
IL-33 IL-1F11 ST2 IL-1RAcP IL-1R4 IL-1R3 Inflammation, Th2 cell responses
IL-36a IL-1F6 IL-1Rrp2 (IL-36R) IL-1RAcP IL-1R6 IL-1R3 Skin and lung inflammation
IL-36b IL-1F7 IL-1Rrp2 (IL-36R) IL-1RAcP IL-1R6 IL-1R3
IL-36g IL-1F8 IL-1Rrp2 (IL-36R) IL-1RAcP IL-1R6 IL-1R3
IL-36Ra IL-1F5 IL-1Rrp2 (IL-36R) IL-1R6 Inhibition of inflammation
IL-37 IL-1F7 IL-18Ra Inhibition of inflammation
IL-38 IL-1F10 IL-1Rrp2 (IL-36R) Inhibition of inflammation
TIR8 (SIGIRR) IL-1R8 Inhibition of inflammation
TIGIRR-1 (IL1RAPL2) IL-1R9 not known
TIGIRR-2 IL-1R10 not known
IL-1R1 (?) IL-1RAcPb IL-1R3b Inhibition of inflammation
?, not formally proven to interact with IL-1RAcPb.
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amounts of actively secreted IL-1b. Elevated secretion of IL-1b is
linked to inflammation in patients with these mutations, termed
autoinflammatory diseases. However, not all IL-1b-mediated
inflammation is due to NLRP3 or caspase-1 activity. Mice defi-
cient in caspase-1 develop the same IL-1b-mediated disease
as do wild-type (WT) mice (Dinarello, 2009, 2011). Extracellular
cleavage of the inactive IL-1b precursor by neutrophil enzymes
such a proteinase-3 and elastase generate active IL-1b because
the cleavage site is close to that of caspase-1 (Dinarello, 2011). In
addition, caspase-11 provides a noncanonical inflammasome
component important for the response to cholera toxin B or
selected microbes (Kayagaki et al., 2011).
Another distinction between IL-1a and IL-1b can be found in
carcinogenesis; mice deficient in IL-1b develop fewer tumors
compared IL-1a-deficient orWTmice (Krelin et al., 2007). IL-1b in-
duces tumor angiogenesis and metastatic spread of tumors
(Carmi et al., 2013). IL-1 is indeed an important component of
the inflammatory microenvironment of tumors (Mantovani et al.,
2008). Early observations on augmentation of metastasis by IL-1
were subsequently extended to primary carcinogenesis in
different organs (Apte et al., 2006; Salcedo et al., 2013). IL-1a is
a component of the intrinsic pathway linking genetic events
causing cancer (Ras mutation) and the orchestration of cancer-
related inflammation (Salcedo et al., 2013). Moreover, IL-1 plays
a critical role in inflammatory conditions that increase cancer inci-
dence (extrinsic pathway) as revealed by carcinogenesis in the
pancreas, skin, and liver (Salcedo et al., 2013). Given the diversity
of cancer-related inflammation in different organs, exploitation of
anti-IL-1 strategies in humancancerwill require careful dissection
of its role indifferent humanneoplasms.Neutralizing antibodies to
IL-1a have entered clinical trial in cachectic patients with terminal
colon cancer with encouraging results (Hong et al., 2011).
Differences between IL-1a and IL-1b are for the most part dif-
ferences due to cell sources of each cytokine and release mech-anisms but not to differences in downstream events following
receptor engagement. Having said that, IL-1a localizes to the
nucleus and functions as a component of transcription, whereas
IL-1b has never been observed in the nucleus. The propiece of
IL-1a contains a string of basic amino acids termed the nuclear
localization sequence (NLS). The NLS accounts for the binding
of the entire IL-1a precursor to DNA. The IL-1a propiece itself
might act as an oncoprotein, and expression of the propiece in-
duces neoplastic changes in cells. The IL-1a precursor shuttles
between the cytosol and nucleus with amazing rapidity (Cohen
et al., 2010). Upon a signal to initiate apoptosis, cytosolic IL-1a
moves to the nucleus and remains tightly bound to chromatin.
In contrast, with a signal to undergo necrosis, for example due
to hypoxia, IL-1a leaves the nucleus and resides in the cytosolic
compartment (Cohen et al., 2010). With necrotic cell death, the
IL-1a precursor is released (Rider et al., 2011), initiating neutro-
philic inflammation (Rider et al., 2011), whereas in cells dying
of apoptosis, chromatin-bound IL-1a is unavailable for initiating
inflammation.
IL-1 production can be a consequence of alterations in the
homeostatic metabolic state as observed in obesity (dysbiosis)
(Tack et al., 2012) (Figure 2A). Recent results have highlighted
differential induction and role of IL-1a and IL-1b in fat induced
vascular responses and atherosclerosis (Freigang et al., 2013).
Atheroma formation has long been associated with IL-1b. In an
unexpected twist, fatty acids were found to elicit release of IL-
1a but not of IL-1b. This selective induction was secondary
to mitochondrial uncoupling that blocked cholesterol crystal-
elicited IL-1b production. Thus metabolic stress triggers a selec-
tive IL-1a-sustained pathway of vascular inflammation and
pathology.
IL-1 is likely to orient macrophages to aerobic glycolysis as
lipopolysaccharide (LPS) does (Rodrı´guez-Prados et al., 2010)
and in turn it is downstream of metabolic responses elicited
by microbial sensing. Accumulation of succinate in classicallyImmunity 39, December 12, 2013 ª2013 Elsevier Inc. 1005
Table 2. Main Phenotype of IL-1 Family Gene Alterations in Mice and Humans
Genetic Deficiency Main Phenotypes Selected References
Il1rn (Il-1ra, mouse) Spontaneous arteritis, arthritis, psoriatic-like
skin eruption, increased susceptibility to LPS,
and to carcinogenesis
(Horai et al., 2000; Krelin et al., 2007;
Nicklin et al., 2000)
IL1RN (IL-1Ra, human) Severe systemic and local inflammation, including
pustular skin eruptions, vasculitis, osteolytic
lesions, and sterile osteomyelitis
(Aksentijevich et al., 2009; Reddy
et al., 2009)
Il1a (mouse) Increased susceptibility to LPS, defective immunoediting
in carcinogenesis, reduced necrosis-induced inflammation,
and colitis, reduced atherosclerosis
(Chen et al., 2007; Krelin et al., 2007)
Il1b (mouse) Reduced acute phase response and fever, increased or
decreased susceptibility to specific infections, reduced
susceptibility to carcinogenesis
(Horai et al., 2000; Krelin et al., 2007)
Il1r1 (mouse) Increased or decreased susceptibility to specific infections,
reduced susceptibility to EAE, reduced inflammatory
responses, and delayed type hypersensitivity, defective
adaptive immunity to tumors and infections
(Sutton et al., 2006; Joeckel et al., 2012;
Ghiringhelli et al., 2009; Ben-Sasson
et al., 2013)
Il18 (mouse) Spontaneous metabolic syndrome, reduced susceptibility
to LPS, arthritis, Fas ligand-mediated hepatitis, graft-versus-
host disease, reduced susceptibility to EAE, increased
susceptibility to colitis and colon-carcinogenesis
(Netea et al., 2006; Dinarello, 2009;
Salcedo et al., 2013)
Il18r1 (IL-18ra, mouse) Increased susceptibility to EAE, spontaneous metabolic
syndrome, increased susceptibility to colitis, and colon-
carcinogenesis
(Netea et al., 2006; Dinarello, 2009;
Salcedo et al., 2013)
Il33 (mouse) Decreased resistance to parasites, reduced inflammatory
and allergic responses, reduced colitis
(Oboki et al., 2010; Liew et al., 2010)
Il1rl1 (St2, mouse) Decreased resistance to parasites and bacteria, reduced
arthritis and colitis, decreased Th2 responses, reduced
endotoxin tolerance
(Neill et al., 2010; Liew et al., 2010)
Il37 Tg (transgenic mouse) Decreased susceptibility to LPS, DSS-induced colitis,
ischemic heart injury, liver ischemia and reperfusion,
defective adaptive immunity.
(Nold et al., 2010; McNamee et al., 2011;
Yousif et al., 2011; Sakai et al., 2012;
Luo et al., 2013)
IL36ATg (IL-36a, transgenic mouse) Psoriasis (Blumberg et al., 2007)
Il1f5 (IL-36ra, mouse) Psoriasis (Tortola et al., 2012)
IL36RN (IL-36Ra, human) Severe psoriasis (Marrakchi et al., 2011)
Il1rl2 (IL-36r, mouse) Reduced psoriasiformis dermatitis (Tortola et al., 2012)
Sigirr (Tir8, mouse) Increased susceptibility to DSS-induced colitis, colon
carcinogenesis, bacterial and fungal infections,
autoimmunity including LES, arthritis, psoriasis and
EAE, leukemia, allergy, kidney ischemia/reperfusion
(Garlanda et al., 2004; Xiao et al., 2007;
Wald et al., 2003; Garlanda et al., 2007b;
Lech et al., 2008; Bulek et al., 2009; Gulen
et al., 2010; Bertilaccio et al., 2011)
Immunity
ReviewactivatedM1macrophages (Tannahill et al., 2013) stabilizes hyp-
oxia-inducible factor a (HIF-1a), which in turn induces IL-1b.
Thus, a metabolic signal represented by succinate serves as a
selective trigger of HIF-1a-dependent IL-1b production and as
an amplifier of innate immunity and inflammation.
IL-33
IL-33 is a cytokine mainly involved in type 2 immunity and inflam-
mation. Its main effects on innate and adaptive cells, including
innate lymphoid cell-2 (ILC2), T helper 2 (Th2) cells, and alterna-
tively activated M2 polarized macrophages, are consistent with
this general function (Figure 2B).
IL-33 is a 30 kDa protein, composed of an N-terminal domain
containing a chromatin bindingmotif and a 18 kDa C-terminal re-
gion rich in b sheets, expressed in a constitutive or inducible
manner by several stromal, parenchymal, and hematopoietic1006 Immunity 39, December 12, 2013 ª2013 Elsevier Inc.cell types. IL-33 is inactivated by caspase-1 (Cayrol and Girard,
2009), and the 30 KDa protein is one of its bioactive forms. IL-33
is released as a bioactive molecule mainly upon necrotic cell
death or secreted by unconventional mechanisms. As for other
IL-1 familymembers, calpain and the neutrophil serine proteases
cathepsin G and elastase cleave human IL-33 and generate
more potent mature forms (Lefranc¸ais et al., 2012).
Figure 2B presents in a schematic way the spectrum of action
of IL-33. Mature IL-33 signals through the ST2 receptor, which
associates with IL-1RAcP to induceMyD88-dependent signaling
(Figure 1A). The crystal structure of IL-33 in complex with the ec-
todomain of ST2 has recently been solved (Liu et al., 2013). ST2
is expressed on various innate and adaptive immune cell types
and drives the production of type 2 cytokines, which are respon-
sible of protective type 2 inflammatory responses in infection
and tissue repair, as well as of detrimental allergic responses.
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Figure 2. IL-1 and IL-33 in Innate and Adaptive Immunity
A schematic representation of role of IL-1 (A) and IL-33 (B) in innate and adaptive immunity. ‘‘+IL-12’’ refers to costimulation by IL-33 + IL-12 of target cells. PRR,
pattern recognition receptor; Nc Th1, nonconventional Th1; a1AT, a1 antitrypsin inhibitor; CRP, C reactive protein; PTX3, pentraxin 3; HPA, hypothalamus-
pituitary-adrenal axis; FFA, free fatty acid.




ReviewGenetic variation in the coding region at the IL1RL1, the gene
coding for ST2, results in different concentrations of soluble
ST2 (Ho et al., 2013).
Negative regulation of IL-33 activity is provided by soluble ST2
and soluble IL-1RAcP, which together bind IL-33 and prevent
its activity. In addition, TIR8 has been reported to negatively
regulate IL-33-dependent signaling and IL-33-driven allergic
responses (Bulek et al., 2009). Finally, negative regulation of IL-
33-dependent lung inflammation is exerted through posttransla-
tional regulation of IL-33R expression by polyubiquitinilation and
degradation (Zhao et al., 2012).
IL-33-activated dendritic cells (DCs) favor polarization of Th2
cells (Besnard et al., 2011). By inducing IL-5 production in
several cell types, ILCs in particular, and by promoting eosinophil
maturation, IL-33 causes eosinophilia in vivo (Bouffi et al., 2013;
Ikutani et al., 2012; Pecaric-Petkovic et al., 2009).
IL-33 amplifies innate immunity and inflammatory responses,
not necessarily dependent on the development of adaptive Th2
cell responses (Oboki et al., 2010). In macrophages, IL-33 favors
LPS-dependent cytokine and chemokine production, and M2
macrophage polarization (Espinassous et al., 2009; Kurowska-
Stolarska et al., 2009). Macrophage-derived IL-33 has been
shown to be a regulator of trophoblast proliferation and placental
growth during early pregnancy (Fock et al., 2013). In a murine
model of sepsis, IL-33 has been found to enhance neutrophil
recruitment to the site of infection and bacterial clearance by
preventing TLR-mediated downregulation of the CXCR2 chemo-
kine receptor (Alves-Filho et al., 2010).
IL-33 is a driver of type 2 inflammatory conditions such as
asthma, fibrosis, and response to parasites (Liew et al., 2010;
McHedlidze et al., 2013; Sica et al., 2013). IL-33 plays a key
role in models of allergic lung inflammation, influenza virus, or
A. fumigatus-induced airway hyperreactivity (Albacker et al.,
2013; Tjota et al., 2013). Sources of IL-33 include epithelial cells,
endothelial cells, and fibroblasts. IL-33 targets a wide range of
immunocompetent cells (Figure 2B) and drives Th2 cell polariza-
tion, eosinophil recruitment, goblet cell hyperplasia, and mucus
secretion.
In humans, genome-wide association studies (GWAS) have
identified single nucleotide polymorphisms (SNPs) in the genes
encoding ST2 and IL-33 associated with asthma (Moffatt
et al., 2010). In chronic obstructive pulmonary disease (COPD),
IL-13-dependent lung disease has been shown to depend on
long-term epithelial progenitor cells programmed for excess
IL-33 production (Byers et al., 2013).
IL-33 plays a protective role against parasites ranging from
nematode expulsion to control of Toxoplasma gondii encephali-
tis (Moro et al., 2010; Neill et al., 2010). IL-13 produced by ILCs is
responsible of this protective response (Moro et al., 2010; Neill
et al., 2010). Interestingly, IL-1b suppresses IL-25 and IL-33
production maintaining chronicity of helminthic infection (Zaiss
et al., 2013).
IL-33 has also been shown to be involved in a variety of path-
ological conditions unrelated to type 2 polarization including
arthritis, sepsis, and fungal and viral infections. In cardiovascular
diseasemodels, IL-33 plays a protective role by reducing athero-
sclerotic plaque formation (Miller et al., 2008) or by reducing car-
diac hypertrophy secondary to pressure overload (Sanada et al.,
2007). IL-33 is also involved in inducing ILC2-dependent in-1008 Immunity 39, December 12, 2013 ª2013 Elsevier Inc.creases in eosinophils and M2 polarized macrophages of
visceral adipose tissue, which are implicated in metabolic
homeostasis (Molofsky et al., 2013). A reflection of the role of
IL-33 in diverse pathologies is the finding of the predictive value
of increased ST2 serum concentrations in Graft versus Host
Disease after allogeneic stem cell transplantation (Vander Lugt
et al., 2013).
Thus, IL-33 is a key player in pathological conditions related to
type 2 responses, as well as in unrelated conditions, by affecting
innate and adaptive lymphoid cells (ILC2 and Th2 cells) and by
regulating the function of innate effectors including macro-
phages and mast cells.
IL-18
First described in 1989 as ‘‘interferon-g (IFN-g)-inducing factor,’’
IL-18 is closely related to IL-1b in that both are first synthesized
as inactive precursors, both require caspase-1 for cleavage,
both can be processed extracellularly by proteinase-3, and
both have decoy receptors. Similar to IL-1a, the IL-18 precursor
is found in nearly all the same mesenchymal cells in health in
humans and mice (Puren et al., 1999), and IL-18 is associated
with the monocyte membrane, as is IL-1a (Bellora et al., 2012).
The tertiary structure of the IL-18 precursor is closely related to
that of the IL-37 precursor and the intron-exon borders of the
IL-18 and IL-37 genes suggest a close relationship. Indeed, IL-
37 binds to the IL-18 receptor.
As discussed below, IL-18 is an important component of
polarized Th1 cell and natural killer (NK) cell responses and of
the interplay between macrophages and NK cells (Figure 3A).
IL-18 has been implicated in several autoimmune diseases,
myocardial pathology, emphysema, metabolic syndrome,
psoriasis, inflammatory bowel disease, macrophage activation
syndrome, sepsis, and acute kidney injury. In some models of
disease as in age-related macular degeneration, IL-18 is protec-
tive (Doyle et al., 2012). IL-18 and IL-18R-deficient aged mice
spontaneously develop a metabolic syndrome similar to that of
humans with diabetes, insulin resistance, and atherosclerosis
(Netea et al., 2006).
Induction of IFN-g by IL-18 requires caspase-1 processing
(Siegmund et al., 2001b). Interestingly, Fas-sustained liver
injury is IL-18 dependent but caspase-1 independent, implying
an alternative processing pathway (Brydges et al., 2009). IL-18
can contribute to some of the manifestations of inflamma-
some-mediated caspase-1 activation in autoinflammatory dis-
eases (Towne et al., 2011).
Any phenotypic characteristic of caspase-1-deficient mice
should be studied to assess whether it is due to reduced IL-1b
or IL-18 activity. The caspase-1-deficient mouse is resistant to
dextran sulfate sodium (DSS)-induced colitis (Siegmund et al.,
2001b), but the IL-1b-deficient mouse is susceptible in the same
disease model (Bersudsky et al., 2013). Because neutralizing an-
tibodies to IL-18 are protective in theDSS colitismodel, caspase-
1 deficiency appears to prevent processing of IL-18 (Siegmund
et al., 2001a) rather than IL-1b. On the other hand, there are exam-
ples where caspase-1 processing of IL-18 is not required. For
example, Fas ligand stimulation results in release of biologically
active IL-18 in caspase 1-deficient murine macrophages.
Mice harboring the mutations prevalent in cryopyrin-
associated periodic syndrome (CAPS) spontaneously develop
Figure 3. IL-18 and IL-36 in Innate and Adaptive Immunity
A schematic representation of role of IL-18 (A) and IL-36 (B) in innate and adaptive immunity. ‘‘+’’ refers to costimulation by IL-12, IL-23, or IL-15 of the action of
IL-18 on target cells. SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; GvHD, graft versus host disease.
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Reviewinflammatory characteristics such as neutrophilia and elevated
circulating concentrations of IL-1b and IL-18 and die in the
neonatal period. Genetic analysis suggests that IL-18 and IL-
1b have complementary roles in the pathogenesis of cutaneous
and systemic manifestations of CAPS (Brydges et al., 2013).
In heart ischemia, the inflammatory cascade begins with acti-
vation of caspase-1, which leads to increased release of IL-1b;
IL-1b then increases the processing and release of active IL-18
from the stored pools of the inactive IL-18 precursor (Pomerantz
et al., 2001), and to counter the inflammatory cascade, IL-18BP
reduces the activity of IL-18. Damage to the heart is likely due to
Fas signaling. Fas induces inflammatory cytokine production,including IL-18. In addition to inducing IL-18, Fas signaling acti-
vates caspase-8 in macrophages and dendritic cells, which
results in processing and release of mature IL-1b and IL-18
(Bossaller et al., 2012). Thus, IL-18 is a key component of polar-
ized type 1 innate and adaptive responses. However, its role
extends beyond type 1 immunity to include autoinflammation
and tissue damage.
IL-36
IL-36 family members IL-36a (IL-1F6), IL-36b (IL-1F8), and IL-
36g (IL-1F9) bind to IL-1Rrp2 and use IL-1RAcP as a coreceptor
(Figure 1A) (Dinarello, 2011; Sims and Smith, 2010). IL-36RaImmunity 39, December 12, 2013 ª2013 Elsevier Inc. 1009
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receptor antagonist. IL-36a, IL-36b, IL-36g, and IL-36Ra do not
contain caspase cleavage sites and N-terminal truncation at the
level of the A-X-Asp motif conserved in all IL-1 family members
dramatically increases their proinflammatory activity (Towne
et al., 2011).
IL-36 is produced by innate immune cells and lymphocytes
inducing the production of proinflammatory cytokines, chemo-
kines, and costimulatory molecules, thus promoting Th1 and
Th17 cell polarization (Vigne et al., 2011, 2012) (Figure 3B). There
is evidence that IL-36 is involved in innate immunity and inflam-
mation in the skin and lung where epithelial cells can be a source
of this cytokine. Here IL-36 is involved in pathological conditions
including psoriasis and A. fumigatus infection (Blumberg et al.,
2007; Gresnigt et al., 2013; Tortola et al., 2012). In general, IL-
36mirrors IL-1 andmight serve as an amplifier of innate immunity
and a mediator of inflammation in selected tissues, such as skin
and lung.
IL-37
IL-37 (IL-1F7) has five splice variants, and isoform IL-37b is the
most complete. An instability sequence limits the half-life of IL-
37 mRNA. Although IL-1b or TLRs increase IL-37, the anti-in-
flammatory cytokine-transforming growth factor-b (TGF-b) was
the most effective stimulus (Nold et al., 2010). Gene databases
do not contain a murine homolog for IL-37, but human IL-37 is
functional in mouse cells (Bufler et al., 2002; Sharma et al.,
2008). Silencing of IL-37 in human blood monocytes with siRNA
results in a 2- to 3-fold increase in LPS and IL-1b-induced cyto-
kines (Nold et al., 2010), suggesting that endogenous IL-37
serves as a natural brake of inflammation.
Similar to IL-1a and IL-33, IL-37 is found in the nucleus where
the cytokine functions in transcription suppressing gene expres-
sion (Sharma et al., 2008). The nuclear translocation and anti-in-
flammatory properties of IL-37 appear to be linked to binding to
the Smad3 (Grimsby et al., 2004) transcription factor for the anti-
inflammatory and immunosuppressive properties of TGF-b.
Recombinant IL-37 binds the IL-18Ra chain (Kumar et al.,
2002; Nold et al., 2013). Despite binding to the IL-18Ra chain,
IL-37 does not act as a classical receptor antagonist (Bufler
et al., 2002; Nold-Petry et al., 2009). Available evidence suggests
that IL-37 engages the IL-18Ra to deliver an inhibitory signal by
using TIR8 (Nold et al., 2013).
To define the in vivo function of IL-37, transgenic mice
expressing the full-length IL-37b isoform (IL-37Tg) have been
generated (Nold et al., 2010). IL-37Tgmice are protected against
LPS challenge with less hypothermia, acidosis, hyperkalemia,
hepatitis, dehydration, and inflammatory cytokines (Nold et al.,
2010).
IL-37Tg mice are protected against inflammatory conditions
involving the gut (DSS-induced colitis) (McNamee et al., 2011),
the heart (ischemic heart injury) (Yousif et al., 2011), and the liver
(ischemia and reperfusion) (Sakai et al., 2012). Protection is
associated with decreased concentrations of inflammatory cyto-
kines and chemokines, and increased IL-10 (colitis). In addition,
there is evidence that IL-37 expressing DCs have defective
capacity to activate effective T cell responses and induce T reg-
ulatory cells (Luo et al., 2013). IL-37 thus emerges as an inhibitor
of adaptive immunity.1010 Immunity 39, December 12, 2013 ª2013 Elsevier Inc.IL-38
IL-38 (IL-1F10) was originally identified in silico. The definition of
its precise function requires continued investigation. The IL-38
gene is located in the IL-1 family cluster on chromosome 2
next to the genes encoding IL-1Ra and IL-36Ra. IL-38 shares
41% homology with IL-1Ra, a 43% homology with IL-36Ra
and has a three-dimensional structure similar to IL-1Ra. By
immunohistochemistry, the IL-38 protein is expressed in the
basal epithelia of skin and in proliferating B cells of the tonsil.
The primary translated product, the IL-38 precursor of 152
amino acids, lacks a signal peptide. The natural N terminus is un-
known and there is no caspase-1 consensus cleavage site for IL-
38. The putative antagonistic role of IL-38 is based on its amino
acid homology to the naturally occurring IL-1Ra, as well as the
observation that IL-38binds to theextracellular domainof recom-
binant IL-1R1 (van de Veerdonk et al., 2012). However, in that
study, the binding affinity of recombinant IL-38 was lower than
those of IL-1Ra and IL-1b. IL-38 binds to the extracellular domain
of recombinant IL-1Rrp2 (IL-36R) expressed as an IgG1 fusion
protein (van de Veerdonk et al., 2012). IL-38 does not bind to
IL-1R1, IL-1R3, or to IL-18Rabut only to the IL-36R. In humanpe-
ripheral blood mononuclear cells (PBMC) stimulated with IL-36g
in the presence of IL-38, the production of IL-8 is reduced by
42%. By comparison, the effect of IL-36Ra on IL-36-driven IL-8
is decreased by 75% (van de Veerdonk et al., 2012). It has been
concluded that the ability of IL-38 to act as a receptor antagonist
for the IL-36R has a biological basis but this property of IL-38 is
weak; therefore, IL-38 appears to act as a partial receptor antag-
onist of the IL-36R. In the caseof the IL-36Ra, its antagonist prop-
erty is determined by generating different N termini and testing
forbiological activity (seeabove). Thus it remains unclearwhether
an alternate N terminus might reveal a more robust function for
recombinant IL-38.
Genetic association studies indicate that IL-38 might be
involved in human inflammatory diseases. In a GWAS of 66,185
subjects with elevated CRP, loci implicated in themetabolic syn-
drome include NLRP3, IL-6R, and IL-38 (Dehghan et al., 2011).
Allele combinations that include IL-38 polymorphisms are asso-
ciated with psoriatic arthritis and ankylosing spondylitis (Maksy-
mowych et al., 2006; Rahman et al., 2006), suggesting that IL-38
plays an important role in the pathogenesis of these inflammatory
diseases. Because of the role that Th17 cells play in the patho-
genesis of autoimmune diseases, it is possible that IL-38 is
involved in the regulation of IL-17 production. Indeed, IL-38
inhibitsCandida albicans-induced IL-17, aswell as IL-22 produc-
tion fromhumanmemoryTcells. In thepresenceof IL-38, thepro-
duction of IL-17A is reduced by 37% and IL-22 by 39%. In the
presence of IL-1Ra, the reduction of IL-17A and IL-22 is 82%
and 71%, respectively (van de Veerdonk et al., 2012). Therefore,
if IL-38 is blocking the IL-1 receptor, then the effect is weak
compared to IL-1Ra. Thus, available information suggests that
IL-38 is a negative regulator structurally and functionally related
to receptor antagonists, involved in human inflammation and
autoimmunity. Further work is required to validate this view and
to dissect the mode of action of this cytokine.
Negative Regulators
The IL-1 system is tightly regulated at multiple levels by diverse
mechanisms including receptor antagonists, decoy receptors,
Figure 4. Negative Regulators of the IL-1 Family
icIL-1Ra, two isoforms of intracellular IL-1Ra.
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(Figure 4; Table 2). In addition, soluble forms of signaling recep-
tors or accessory proteins (e.g., ST2 and IL-1RAcP) might act as
decoys or negative regulators by trapping the ligands. The exis-
tence of a wide range of negative regulators emphasizes the
need for tight control of the IL-1 system, which mediates poten-
tially devastating local and systemic inflammatory reactions.
Herewewill focus onmechanisms of negative regulation intrinsic
to the IL-1 family, including decoy receptors, receptor antago-
nists, and TIR8.
The IL-1 receptor family includes two decoy receptors, IL-1R2
and IL-18BP (Figures 1 and 4). IL-1R2 has a short cytoplasmic
tail and no TIR domain and does not signal. It is released in a sol-
uble form (Kuhn et al., 2007; Lorenzen et al., 2012) as a conse-
quence of proteolytic processing or alternative splicing. The
overall structure of the IL-1b-IL-1R2-IL-1RAcP complex is similar
to that of the signaling ligand-receptor complex (Wang et al.,
2010).
IL-1R2 negatively regulates IL-1 activity by different mecha-
nisms (Figure 4). By binding with high affinity, IL-1R2 acts as a
molecular trap for IL-1 (Colotta et al., 1993; Re et al., 1996). Inter-
estingly, IL-1R2 binds IL-1Ra at least 100 times less efficiently
than the agonists. Moreover, IL-1R2 forms a complex with IL-1
and the IL-1RAcP, exerting a dominant-negative effect. Finally,
soluble IL-1R2 and soluble IL-1RAcP bind pro-IL-1bwith high af-
finity and block its processing by caspase-1 (Smith et al., 2003).
IL-1R2 is present in the cytoplasm and interacts with pro-IL-1apreventing cleavage and activation by different enzymes (cal-
pain, granzyme B, chymase, and elastase) (Zheng et al., 2013).
Caspase-1 cleaves IL-1R2 causing dissociation from IL-1a,
calpain processing, and complete restoration of IL-1a activity
after necrosis or during regulated secretion. Because IL-1R2 is
expressed by a limited set of cells, this would represent a further
mechanism of negative control of IL-1a by IL-1R2 during necro-
sis, restricted to specific cell types (Zheng et al., 2013).
In contrast to IL-1R1, which is expressed by a large variety of
cell types, IL-1R2 is expressed by amore limited set of cell types,
including monocytes, polarized M2 macrophages, microglial
cells, neutrophils, B cells, and T regulatory (Treg) cells (Colotta
et al., 1993;Martin et al., 2013;Mercer et al., 2010; Reet al., 1996).
Anti-inflammatory signals enhance IL-1R2 expression,
including glucocorticoid hormones (GCs), prostaglandins, Th2
cell-associated cytokines (IL-4 and IL-13), and IL-27 (Colotta
et al., 1993), suggesting that induction of IL-1R2 contributes to
the anti-inflammatory effect of these mediators. During preg-
nancy, chorionic gonadotropins downregulate the synthesis
and release of IL-1R2 by endometrial epithelial cells, thus favor-
ing embryonic IL-1b activities essential for attachment of the
blastocyst. Increased blood concentrations of IL-1R2 have
been detected in a wide range of human disorders and might
reflect the activation of endogenous pathways of negative regu-
lation of inflammation.
IL-18BP is composed of only one Ig-like domain and is struc-
turally and functionally similar to IL-1R2 (Novick et al., 1999). ByImmunity 39, December 12, 2013 ª2013 Elsevier Inc. 1011
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IL-18 activity, IL-18BP dampens IFN-g production and conse-
quently limits Th1 cell responses (Kim et al., 2000; Novick
et al., 1999) (Figure 4). The gene is induced by IFN-g, thus
indicating that IL-18BP is part of a negative feedback loop
controlling IFN-g-dependent inflammation, and by IL-27. In
homeostatic conditions, IL-18BP is present in the circulation at
concentrations of 20-fold molar excess to IL-18, thus represent-
ing a default mechanism limiting IL-18 activity. In several IFN-g-
mediated autoimmune conditions, the concentrations of free
IL-18 compared to IL-18 bound to IL-18BP is important in deter-
mining the severity of the disease (Novick et al., 2010). IL-18BP
also binds IL-37 complex, and it might act as a dominant-nega-
tive receptor.
The IL-1 ligand family includes two receptor antagonists, IL-
1Ra and IL-36Ra (Dinarello, 2010). IL-1Ra binds IL-1R1 with an
affinity higher than that of IL-1 but fails to recruit the IL-1RAcP.
In addition to secreted soluble IL-1Ra, there are the two intracel-
lular isoforms which are considered a reservoir of IL-1Ra, to be
released upon cell death, limiting the proinflammatory action of
tissue damage.
Deficiency of IL-1Ra in mice results in spontaneous and lethal
arteritis, destructive arthritis, and psoriatic-like skin lesions, as
well as increased susceptibility to carcinogenesis (Horai et al.,
2000; Nicklin et al., 2000). Children bornwith a genetic deficiency
of IL-1Ra or functional inactive IL-1Ra suffer from severe sys-
temic and local inflammation, including pustular skin eruptions,
vasculitis, osteolytic lesions, and sterile osteomyelitis (Aksentije-
vich et al., 2009; Reddy et al., 2009).
IL-36Ra acts as a specific receptor antagonist for IL-1Rrp2
and prevents the activity of IL-36. IL-36Ra negatively regulates
the IL-36-elicited pathway comprising IL-23, IL-17, and IL-22
and development of psoriasiform dermatitis (Blumberg et al.,
2007; Tortola et al., 2012). Mutations of the IL-36Ra gene are
associated to a rare life-threatening form of psoriasis (Marrakchi
et al., 2011).
TIR8 (also known as SIGIRR) is an atypical receptor character-
ized by a single Ig domain and a TIR domain with two substitu-
tions (Ser447 and Tyr536 replaced by Cys222 and Leu305),
which early on suggested nonconventional signaling (Figures
1A and 4). TIR8 is expressed in several tissues, particularly in
the kidney, digestive tract, liver, lung, and lymphoid organs
(Garlanda et al., 2009).
TIR8 inhibits NF-kB and JNK activation following stimulation of
IL-1R family members or TLRs (IL-1RI, IL-18R, ST2, TLR1, TLR2,
TLR3, TLR4, TLR7, and TLR9) (Bulek et al., 2009; Garlanda et al.,
2004; Lech et al., 2008; Wald et al., 2003), by interfering with the
recruitment of TIR-containing adaptor molecules (Wald et al.,
2003). TIR8 can also regulate mTOR kinase activity in Th17 lym-
phocytes (Gulen et al., 2010) and in intestinal epithelial cells (Xiao
et al., 2010).
Studies with deficient mice have shown that TIR8 plays nonre-
dundant roles in regulating potentially detrimental inflammatory
responses associated to infections, such as tuberculosis, candi-
diasis, aspergillosis, and P. aeruginosa infection (Bozza et al.,
2008; Chen et al., 2011; Garlanda et al., 2007a; Huang et al.,
2006). TIR8-deficiency causes more severe gut inflammation
during DSS colitis (Garlanda et al., 2004; Xiao et al., 2007) and
increased susceptibility to intestinal carcinogenesis (Garlanda1012 Immunity 39, December 12, 2013 ª2013 Elsevier Inc.et al., 2007b; Xiao et al., 2007; Xiao et al., 2010). In a murine
model of chronic lymphocytic leukemia (CLL), TIR8-deficiency
leads to a more severe and earlier appearance of monoclonal
B cell expansions and to shortened life span, in agreement
with TIR8 downmodulation in human malignant B cells (Bertilac-
cio et al., 2011).
In kidney ischemia or transplantation, TIR8-deficiency causes
increased renal injury or severe graft rejection, associated with
excessive inflammation and amplified adaptive immune re-
sponses against donor antigens (Lech et al., 2009; Noris et al.,
2009). TIR8 modulated LPS-induced microglia activation and
neuroinflammation, cognitive and synaptic functions in hippo-
campal tissue in response to IL-1a, and high mobility group
box 1.
TIR8-deficiency is also associated with increased suscepti-
bility to develop allergy and autoimmunity in various models
including systemic lupus erythematosus, lupus nephritis (Lech
et al., 2008, 2010), arthritis (Drexler et al., 2010), experimental
autoimmune encephalomyelitis, and psoriasis (Russell et al.,
2013). In the latter cases, TIR8 dampens IL-1-dependent differ-
entiation of Th17 and Tgd17 cells (Gulen et al., 2010; Russell
et al., 2013).
IL-1RAcPb is an alternative form of IL-1RAcP restricted to the
central nervous system (CNS), generated by alternative splicing,
in which the prototypical IL-1RAcP C-terminal exon 12 is skip-
ped and an alternative exon 12b is used (Smith et al., 2009).
The exon 12b encodes a sequence of approximately 140 addi-
tional amino acids in the C-terminal of the TIR domain causing
a changed configuration in the DD loop and aD helix regions of
the IL-1RAcPb TIR domain and affecting the interaction with
MyD88 and IRAK4. IL-1RAcPb could also be recruited to other
IL-1RAcP-utilizing receptors, such as ST2 and IL-1Rrp2, which
are expressed in the CNS. IL-1RAcPb-deficiency is associated
with neuronal loss, suggesting that it might dampen the neuro-
toxic effects of IL-1 by modulating the intracellular signaling
and gene-expression response to LPS-induced IL-1 or possibly
to other cytokines acting through IL-1RAcP (Smith et al., 2009).
Orchestration of Innate and Adaptive Lymphoid Cells
IL-1 family members affect virtually all cells of the innate immune
system, including macrophages, neutrophils, eosinophils, baso-
phils, andmast cells (Figure 2A). This aspect has previously been
reviewed (Dinarello, 2009; Dinarello et al., 2012; Gabay et al.,
2010; Sims and Smith, 2010) and specific topics (e.g., M2
macrophage polarization for IL-33) are discussed above. Here
we will focus on interaction with lymphoid cells.
One of the early descriptions of, and bioassay for, IL-1 was
based on costimulation of T lymphocyte proliferation, the
so-called lymphocyte activation factor (LAF) activity and assay
(Dinarello, 2009). The perception that IL-1 affects lymphoid cells
has waned for a long time to be revisited with the realization that
polarized T cell and ILC differentiation and function involves
members of the IL-1 family (Figure 5) (O’Shea and Paul, 2010;
Spits et al., 2013).
ILCs are a complex and heterogeneous group of lymphoid
cells involved in innate immunity and tissue remodeling (Spits
et al., 2013). ILCs have been recently divided in different func-
tional subsets: group 1 ILCs includes NK cells and other IFN-
g-producing ILCs; group 2 ILCs includes cells that produce
Figure 5. IL-1 Family Members in the Differentiation and Function of Innate and Adaptive Lymphoid Cells
‘‘+’’ above arrows refers to stimulation of target cells by IL-1 family members with or without other cytokines (IL-12, IL-25, thymic stromal lymphopoietin [TSLP],
IL-23). Arrows point to products of stimulated cells and cellular effectors (on the right part). ncTh1, nonconventional Th1 cells (human). The// sign for the Th17
cells and Tgd17 cells indicates the presence of intermediate cells (endothelium, epithelium), which respond to IL-17.
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duce IL-17 and/or IL-22. In analogy with T cell polarization,
ILCs depend on g chain cytokines and IL-1 family members for
their specific development and activity. IL-18, together with IL-
15, is a major stimulus for IFN-g production by group 1 ILCs;
IL-33, acting in synergy with IL-25, is a potent inducer of the
expansion of type 2 ILCs and of the production of extremely
high amounts of Th2 cell-associated cytokines, in particular IL-
5 and IL-13; IL-1b and IL-23 activate group 3 ILCs to produce
IL-17 and IL-22 (Figure 5).
NK cells are prototypic ILC1 cells. IL-18 is a keymediator in the
interaction between NK cells and DC or macrophages (e.g., Bel-
lora et al., 2012; Mailliard et al., 2005). Macrophage-derived
IL-18 promotes NK cell activation and, via DC, activation of
adaptive responses. In secondary lymphoid tissues, DC-derived
IL-1b preferentially promotes ILC3 phenotype and expansion
from immature NK cells, at the expense of development and
maturation of conventional IFN-g-producing NK cells, which
express lower amounts of IL-1R1 (Hughes et al., 2010).
In an interesting unexpected twist, IL-33 has been recently
involved in the response to bee venom phospholipase A2
(PLA2) (Palm et al., 2013). PLA2, a conserved component of
many venoms, triggers release of IL-33 and activation of
ILC2s. The adaptive Th2 response against PLA2 is also IL-33
and ST2 dependent. Thus IL-33 is a key element of the innate
response to a conserved component of venoms.
IL-1 family members are key components of T cell polarization
and function (O’Shea and Paul, 2010). IL-18 was originally iden-
tified based on its capacity to costimulate IFN-g production. It is
therefore not surprising that IL-18 has been associated with Th1
cell differentiation (Santarlasci et al., 2013). IL-18 is dispensablefor recruitment of naive T cells to become Th1 cells. The IL-18R is
induced by IL-12 in Th1 cells, and this cytokine amplifies their
expansion and IFN-g production.
It has long been held that IL-1R1 is not expressed in Th1 cells.
Recent results with human lymphocytes dispel this oversimplifi-
cation. It has found that a subset of Th1 clones, in particular
those characterized by expression of CD161, expresses IL-
1R1 (Cosmi et al., 2008; Maggi et al., 2012). These ‘‘nonclas-
sical’’ Th1 cells derive from Th17 cells. Thus, expression of
IL-1R is a feature of ‘‘nonclassical’’ Th1 cells ontogenetically
related to Th17 cells. The actual role of IL-1 in the function of
this Th1 subset remains to be elucidated.
The IL-1 familymember associated with Th2 cell differentiation
and function is IL-33 (see above). Unlike Th1 cells, Th2 cells
express the IL-33 receptor chain ST2 (Guo et al., 2009). IL-33
is dispensable for Th2 cell differentiation but it amplifies cytokine
production (in particular IL-5 and IL-13) by these cells.
Analysis of the differentiation of human naive T cells to Th17
cells originally revealed a key role of IL-1 (Acosta-Rodriguez
et al., 2007; Annunziato et al., 2007). Accordingly, IL-1 is required
for development of Th17 cell-sustained autoimmunity (e.g.,
Chung et al., 2009; Sutton et al., 2006; Veldhoen et al., 2006).
IL-1 has more subtle actions in Th17 cells than promotion of
differentiation. Candida albicans- and Staphylococcus aureus-
specific human Th17 cells produce IL-17, but differ in terms of
IL-10 and IFN-g. IL-1 is essential to generate C. albicans-
induced cells capable of producing both IL-17 and IFN-g. IL-1
also inhibits IL-10 production, which otherwise dampens IFN-g
secretion (Zielinski et al., 2012). Thus, IL-1 plays a role in fine-
tuning the cytokine repertoire of Th17 cells specific for different
pathogens.Immunity 39, December 12, 2013 ª2013 Elsevier Inc. 1013
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et al., 2013). IL-1 is not required for thymic differentiation of Tgd17.
However, Tgd17 express the IL-1R and IL-1 in concert with IL-23
drives their activation and IL-1 production, thus setting in motion
an amplification circuit (Duan et al., 2010; Zeng et al., 2012).
Methicillin-resistant Staphilococcus aureus represents a
serious clinical problem. In a mouse model of skin infection,
resistance to S. aureus depends on IL-1, which promotes IL-17
production by Tgd cells (Myles et al., 2013). Keratinocytes and
possibly myeloid cells are the major source of IL-1b. The same
cells produce IL-19, IL-20, and IL-24, three members of the IL-
10 family. These cytokines act via the IL-20 receptor and elicit
degradation of the transcription factor cEBP, thus resulting in
feedback inhibition of IL-1.
iNKT cells respond to IL-1 and IL-18. IL-1, together with other
cytokines, has been reported to induce IL-17 production by iNKT
cells and, in the context of viral infection, IL-22 (Doisne et al.,
2011; Monteiro et al., 2013; Paget et al., 2012).
IL-1R1-deficient mice show defective capacity to generate
effective CD8+ T cell responses to viruses (e.g., Joeckel et al.,
2012) and tumors (Ghiringhelli et al., 2009). By using the OT-1
model, it has recently reported that IL-1b results in increased
numbers and effector function of antigen-specific T cells. The ef-
fect of IL-1 includes the amplification of the memory response
(Ben-Sasson et al., 2013). This finding raises the issue of the
possible use of IL-1 as an adjuvant to stimulate CD8+ T cell
response.
Therapeutic Strategies for IL-1 Blockade in Human
Diseases
Anakinra is the generic name for the recombinant form of the
naturally occurring IL-1Ra and has been approved in 2001 to
treat rheumatoid arthritis and recently to treat CAPS. However,
Anakinra has proved efficacious in a broad spectrum of diseases
and is currently in several clinical trials (Dinarello et al., 2012).
These include autoimmune hearing loss, hydradenitis suppura-
tiva, stroke, and osteoarthritis of the hand. The responses to ana-
kinra are rapid and sustained and in many conditions, treatment
with anakinra allows for a reduction in steroid use, particularly in
children with systemic juvenile idiopathic arthritis. Anakinra is
also used to treat common diseases such as recurrent gout
attacks unresponsive to standards of therapy.
There is a large body of preclinical evidence supporting the
rationale for specifically targeting IL-1b with neutralizing anti-
bodies. In autoinflammatory diseases, IL-1b is released from
the activated monocyte as a result of dysregulation of cas-
pase-1. Canakinumab is a human monoclonal antibody specif-
ically targeting IL-1b, which is approved for the treatment of
CAPS, systemic onset juvenile idiopathic arthritis, and refractory
gout. It will be tested in a large trial in cardiovascular pathology. A
neutralizing monoclonal anti-IL-1a antibody has been tested in
Type 2 diabetes, cancer cachexia, pustular psoriasis, occlusive
vascular disease, and scarring acne vulgaris and in each condi-
tion, reduced disease severity has been observed in limited trials
(Hong et al., 2011).
Concluding Remarks
Evidence obtained in the last few years indicates that members
of the IL-1 family are key players in the differentiation and func-1014 Immunity 39, December 12, 2013 ª2013 Elsevier Inc.tion of innate and adaptive lymphoid cells. Thus, in a way, the
long overlooked costimulating activity of IL-1 (LAF) has now
been vindicated by the discovery of its role in innate and adaptive
lymphoid cell differentiation and function.
Early work had shown that IL-1 has adjuvant activity (Dinarello,
2009) and activation of the inflammasome might contribute to
the function of adjuvants in current clinical use. The identification
of the role of IL-1 family members in lymphoid differentiation
raises the issue as to whether this aspect of the function of
IL-1 family members can be harnessed for better vaccines
(e.g., Ben-Sasson et al., 2013).
The IL-1 system is characterized by the recurrent theme of
balancing accelerators and brakes (receptor antagonists, decoy
receptors, TIR8). Scattered evidence suggests that negative reg-
ulators are key components of resolution of inflammation. It is
tempting to speculate that these components of the IL-1 family
might represent therapeutic targets in proresolving strategies.
Anti-IL-1 strategies have had a tremendous impact in the ther-
apy of autoinflammatory disorders sustained by inflammasome
activation and, to a lesser extent, autoimmune diseases (Dinar-
ello, 2010). Ongoing studies suggest that blocking IL-1 might
have a broader clinical impact on relatively rare (e.g., Behcet
uveitis) and common (e.g., cardiovascular) diseases. Better
understanding of the pathophysiology of IL-1 and its relatives
holds promise of innovative therapeutic tools and targets: hic
sunt leones.
ACKNOWLEDGMENTS
A.M. and C.G. are supported by European Research Council (Project HIIIS),
European Commission (FP7-HEALTH-2011- ADITEC 280873), and Associa-
zione Italiana per la Ricerca sul Cancro (AIRC). C.A.D. is supported by the
National Institutes of Health Grants A115614 and AR-45584. A.M. and C.G.
are inventors in patents related to the IL-1 inducible gene PTX3, and Human-
itas receives royalties to IL-1 family reagents.
REFERENCES
Acosta-Rodriguez, E.V., Napolitani, G., Lanzavecchia, A., and Sallusto, F.
(2007). Interleukins 1beta and 6 but not transforming growth factor-beta are
essential for the differentiation of interleukin 17-producing human T helper
cells. Nat. Immunol. 8, 942–949.
Aksentijevich, I., Masters, S.L., Ferguson, P.J., Dancey, P., Frenkel, J., van
Royen-Kerkhoff, A., Laxer, R., Tedga˚rd, U., Cowen, E.W., Pham, T.H., et al.
(2009). An autoinflammatory disease with deficiency of the interleukin-1-
receptor antagonist. N. Engl. J. Med. 360, 2426–2437.
Albacker, L.A., Chaudhary, V., Chang, Y.J., Kim, H.Y., Chuang, Y.T., Picha-
vant, M., DeKruyff, R.H., Savage, P.B., and Umetsu, D.T. (2013). Invariant nat-
ural killer T cells recognize a fungal glycosphingolipid that can induce airway
hyperreactivity. Nat. Med. 19, 1297–1304.
Alves-Filho, J.C., Soˆnego, F., Souto, F.O., Freitas, A., Verri, W.A., Jr., Auxilia-
dora-Martins, M., Basile-Filho, A., McKenzie, A.N., Xu, D., Cunha, F.Q., and
Liew, F.Y. (2010). Interleukin-33 attenuates sepsis by enhancing neutrophil
influx to the site of infection. Nat. Med. 16, 708–712.
Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B.,
Parente, E., Filı`, L., Ferri, S., Frosali, F., et al. (2007). Phenotypic and functional
features of human Th17 cells. J. Exp. Med. 204, 1849–1861.
Apte, R.N., Dotan, S., Elkabets, M., White, M.R., Reich, E., Carmi, Y., Song, X.,
Dvozkin, T., Krelin, Y., and Voronov, E. (2006). The involvement of IL-1 in
tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions.
Cancer Metastasis Rev. 25, 387–408.
Bellora, F., Castriconi, R., Doni, A., Cantoni, C., Moretta, L., Mantovani, A.,
Moretta, A., and Bottino, C. (2012). M-CSF induces the expression of a
Immunity
Reviewmembrane-bound form of IL-18 in a subset of human monocytes differenti-
ating in vitro toward macrophages. Eur. J. Immunol. 42, 1618–1626.
Ben-Sasson, S.Z., Hogg, A., Hu-Li, J., Wingfield, P., Chen, X., Crank, M., Cau-
cheteux, S., Ratner-Hurevich, M., Berzofsky, J.A., Nir-Paz, R., and Paul, W.E.
(2013). IL-1 enhances expansion, effector function, tissue localization, and
memory response of antigen-specific CD8 T cells. J. Exp. Med. 210, 491–502.
Berda-Haddad, Y., Robert, S., Salers, P., Zekraoui, L., Farnarier, C., Dinarello,
C.A., Dignat-George, F., and Kaplanski, G. (2011). Sterile inflammation of
endothelial cell-derived apoptotic bodies is mediated by interleukin-1a.
Proc. Natl. Acad. Sci. USA 108, 20684–20689.
Bersudsky, M., Luski, L., Fishman, D., White, R.M., Ziv-Sokolovskaya, N.,
Dotan, S., Rider, P., Kaplanov, I., Aychek, T., Dinarello, C.A., et al. (2013).
Non-redundant properties of IL-1a and IL-1b during acute colon inflammation
in mice. Gut, in press.
Bertilaccio, M.T., Simonetti, G., Dagklis, A., Rocchi, M., Rodriguez, T.V., Apol-
lonio, B., Mantovani, A., Ponzoni, M., Ghia, P., Garlanda, C., et al. (2011). Lack
of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia inmouse
models. Blood 118, 660–669.
Besnard, A.G., Togbe, D., Guillou, N., Erard, F., Quesniaux, V., and Ryffel, B.
(2011). IL-33-activated dendritic cells are critical for allergic airway inflamma-
tion. Eur. J. Immunol. 41, 1675–1686.
Blumberg, H., Dinh, H., Trueblood, E.S., Pretorius, J., Kugler, D., Weng, N.,
Kanaly, S.T., Towne, J.E., Willis, C.R., Kuechle, M.K., et al. (2007). Opposing
activities of two novel members of the IL-1 ligand family regulate skin inflam-
mation. J. Exp. Med. 204, 2603–2614.
Bossaller, L., Chiang, P.I., Schmidt-Lauber, C., Ganesan, S., Kaiser, W.J.,
Rathinam, V.A., Mocarski, E.S., Subramanian, D., Green, D.R., Silverman,
N., et al. (2012). Cutting edge: FAS (CD95) mediates noncanonical IL-1b and
IL-18 maturation via caspase-8 in an RIP3-independent manner. J. Immunol.
189, 5508–5512.
Bouffi, C., Rochman, M., Zust, C.B., Stucke, E.M., Kartashov, A., Fulkerson,
P.C., Barski, A., and Rothenberg, M.E. (2013). IL-33markedly activates murine
eosinophils by an NF-kB-dependentmechanismdifferentially dependent upon
an IL-4-driven autoinflammatory loop. J. Immunol. 191, 4317–4325.
Bozza, S., Zelante, T., Moretti, S., Bonifazi, P., DeLuca, A., D’Angelo, C.,
Giovannini, G., Garlanda, C., Boon, L., Bistoni, F., et al. (2008). Lack of Toll
IL-1R8 exacerbates Th17 cell responses in fungal infection. J. Immunol. 180,
4022–4031.
Brydges, S.D., Mueller, J.L., McGeough, M.D., Pena, C.A., Misaghi, A., Gan-
dhi, C., Putnam, C.D., Boyle, D.L., Firestein, G.S., Horner, A.A., et al. (2009).
Inflammasome-mediated disease animal models reveal roles for innate but
not adaptive immunity. Immunity 30, 875–887.
Brydges, S.D., Broderick, L., McGeough, M.D., Pena, C.A., Mueller, J.L., and
Hoffman, H.M. (2013). Divergence of IL-1, IL-18, and cell death in NLRP3
inflammasomopathies. J. Clin. Invest., in press.
Bufler, P., Azam, T., Gamboni-Robertson, F., Reznikov, L.L., Kumar, S., Dinar-
ello, C.A., and Kim, S.H. (2002). A complex of the IL-1 homologue IL-1F7b and
IL-18-binding protein reduces IL-18 activity. Proc. Natl. Acad. Sci. USA 99,
13723–13728.
Bulek, K., Swaidani, S., Qin, J., Lu, Y., Gulen, M.F., Herjan, T., Min, B., Kaste-
lein, R.A., Aronica, M., Kosz-Vnenchak, M., and Li, X. (2009). The essential role
of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2
immune response. J. Immunol. 182, 2601–2609.
Byers, D.E., Alexander-Brett, J., Patel, A.C., Agapov, E., Dang-Vu, G., Jin, X.,
Wu, K., You, Y., Alevy, Y., Girard, J.P., et al. (2013). Long-term IL-33-producing
epithelial progenitor cells in chronic obstructive lung disease. J. Clin. Invest.
123, 3967–3982.
Carmi, Y., Dotan, S., Rider, P., Kaplanov, I., White, M.R., Baron, R., Abutbul,
S., Huszar, M., Dinarello, C.A., Apte, R.N., and Voronov, E. (2013). The role
of IL-1b in the early tumor cell-induced angiogenic response. J. Immunol.
190, 3500–3509.
Cayrol, C., and Girard, J.P. (2009). The IL-1-like cytokine IL-33 is inactivated
after maturation by caspase-1. Proc. Natl. Acad. Sci. USA 106, 9021–9026.
Chen, C.J., Kono, H., Golenbock, D., Reed, G., Akira, S., and Rock, K.L. (2007).
Identification of a key pathway required for the sterile inflammatory response
triggered by dying cells. Nat. Med. 13, 851–856.Chen, X., Zhao, Y., Wu, X., and Qian, G. (2011). Enhanced expression of single
immunoglobulin IL-1 receptor-related molecule ameliorates LPS-induced
acute lung injury in mice. Shock 35, 198–204.
Chien, Y.H., Zeng, X., and Prinz, I. (2013). The natural and the inducible: inter-
leukin (IL)-17-producing gd T cells. Trends Immunol. 34, 151–154.
Chung, Y., Chang, S.H., Martinez,G.J., Yang, X.O., Nurieva, R., Kang, H.S.,Ma,
L.,Watowich, S.S., Jetten,A.M., Tian,Q., andDong,C. (2009).Critical regulation
ofearlyTh17cell differentiationby interleukin-1signaling. Immunity30, 576–587.
Cohen, I., Rider, P., Carmi, Y., Braiman, A., Dotan, S.,White,M.R., Voronov, E.,
Martin, M.U., Dinarello, C.A., and Apte, R.N. (2010). Differential release of chro-
matin-bound IL-1alpha discriminates between necrotic and apoptotic cell
death by the ability to induce sterile inflammation. Proc. Natl. Acad. Sci.
USA 107, 2574–2579.
Colotta, F., Re, F., Muzio, M., Bertini, R., Polentarutti, N., Sironi, M., Giri, J.G.,
Dower, S.K., Sims, J.E., and Mantovani, A. (1993). Interleukin-1 type II recep-
tor: a decoy target for IL-1 that is regulated by IL-4. Science 261, 472–475.
Cosmi, L., De Palma, R., Santarlasci, V., Maggi, L., Capone, M., Frosali, F.,
Rodolico, G., Querci, V., Abbate, G., Angeli, R., et al. (2008). Human interleukin
17-producing cells originate from a CD161+CD4+ T cell precursor. J. Exp.
Med. 205, 1903–1916.
Dehghan, A., Dupuis, J., Barbalic, M., Bis, J.C., Eiriksdottir, G., Lu, C., Pellikka,
N., Wallaschofski, H., Kettunen, J., Henneman, P., et al. (2011). Meta-analysis
of genome-wide association studies in >80 000 subjects identifiesmultiple loci
for C-reactive protein levels. Circulation 123, 731–738.
Dinarello, C.A. (2009). Immunological and inflammatory functions of the inter-
leukin-1 family. Annu. Rev. Immunol. 27, 519–550.
Dinarello, C.A. (2010). Anti-inflammatory Agents: Present and Future. Cell 140,
935–950.
Dinarello, C.A. (2011). Interleukin-1 in the pathogenesis and treatment of
inflammatory diseases. Blood 117, 3720–3732.
Dinarello, C., Arend, W., Sims, J., Smith, D., Blumberg, H., O’Neill, L., Gold-
bach-Mansky, R., Pizarro, T., Hoffman, H., Bufler, P., et al. (2010). IL-1 family
nomenclature. Nat. Immunol. 11, 973.
Dinarello, C.A., Simon, A., and van der Meer, J.W. (2012). Treating inflamma-
tion by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug
Discov. 11, 633–652.
Doisne, J.M., Soulard, V., Be´court, C., Amniai, L., Henrot, P., Havenar-Daugh-
ton, C., Blanchet, C., Zitvogel, L., Ryffel, B., Cavaillon, J.M., et al. (2011).
Cutting edge: crucial role of IL-1 and IL-23 in the innate IL-17 response of
peripheral lymph node NK1.1- invariant NKT cells to bacteria. J. Immunol.
186, 662–666.
Doyle, S.L., Campbell, M., Ozaki, E., Salomon, R.G., Mori, A., Kenna, P.F., Far-
rar, G.J., Kiang, A.S., Humphries, M.M., Lavelle, E.C., et al. (2012). NLRP3 has
a protective role in age-related macular degeneration through the induction of
IL-18 by drusen components. Nat. Med. 18, 791–798.
Drexler, S.K., Kong, P., Inglis, J., Williams, R.O., Garlanda, C., Mantovani, A.,
Yazdi, A.S., Brennan, F., Feldmann, M., and Foxwell, B.M. (2010). SIGIRR/
TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and
regulates inflammation in models of rheumatoid arthritis. Arthritis Rheum.
62, 2249–2261.
Duan, J., Chung, H., Troy, E., and Kasper, D.L. (2010). Microbial colonization
drives expansion of IL-1 receptor 1-expressing and IL-17-producing
gamma/delta T cells. Cell Host Microbe 7, 140–150.
Espinassous, Q., Garcia-de-Paco, E., Garcia-Verdugo, I., Synguelakis,M., von
Aulock, S., Sallenave, J.M., McKenzie, A.N., and Kanellopoulos, J. (2009). IL-
33 enhances lipopolysaccharide-induced inflammatory cytokine production
from mouse macrophages by regulating lipopolysaccharide receptor com-
plex. J. Immunol. 183, 1446–1455.
Fock, V., Mairhofer, M., Otti, G.R., Hiden, U., Spittler, A., Zeisler, H., Fiala, C.,
Kno¨fler, M., and Pollheimer, J. (2013). Macrophage-derived IL-33 is a critical
factor for placental growth. J. Immunol. 191, 3734–3743.
Freigang, S., Ampenberger, F., Weiss, A., Kanneganti, T.D., Iwakura, Y., Hers-
berger, M., and Kopf, M. (2013). Fatty acid-induced mitochondrial uncoupling
elicits inflammasome-independent IL-1a and sterile vascular inflammation in
atherosclerosis. Nat. Immunol. 14, 1045–1053.Immunity 39, December 12, 2013 ª2013 Elsevier Inc. 1015
Immunity
ReviewGabay, C., Lamacchia, C., and Palmer, G. (2010). IL-1 pathways in inflamma-
tion and human diseases. Nat Rev Rheumatol 6, 232–241.
Garlanda, C., Riva, F., Polentarutti, N., Buracchi, C., Sironi, M., De Bortoli, M.,
Muzio, M., Bergottini, R., Scanziani, E., Vecchi, A., et al. (2004). Intestinal
inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor
family. Proc. Natl. Acad. Sci. USA 101, 3522–3526.
Garlanda, C., Di Liberto, D., Vecchi, A., La Manna, M.P., Buracchi, C., Cac-
camo, N., Salerno, A., Dieli, F., and Mantovani, A. (2007a). Damping excessive
inflammation and tissue damage in Mycobacterium tuberculosis infection by
Toll IL-1 receptor 8/single Ig IL-1-related receptor, a negative regulator of
IL-1/TLR signaling. J. Immunol. 179, 3119–3125.
Garlanda, C., Riva, F., Veliz, T., Polentarutti, N., Pasqualini, F., Radaelli, E.,
Sironi, M., Nebuloni, M., Zorini, E.O., Scanziani, E., and Mantovani, A.
(2007b). Increased susceptibility to colitis-associated cancer of mice lacking
TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res.
67, 6017–6021.
Garlanda, C., Anders, H.J., and Mantovani, A. (2009). TIR8/SIGIRR: an IL-1R/
TLR family member with regulatory functions in inflammation and T cell polar-
ization. Trends Immunol. 30, 439–446.
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermae-
len, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009). Activation of the
NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive
immunity against tumors. Nat. Med. 15, 1170–1178.
Gresnigt, M.S., Ro¨sler, B., Jacobs, C.W., Becker, K.L., Joosten, L.A., van der
Meer, J.W., Netea,M.G., Dinarello, C.A., and van de Veerdonk, F.L. (2013). The
IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and
Th17 responses. Eur. J. Immunol. 43, 416–426.
Grimsby, S., Jaensson, H., Dubrovska, A., Lomnytska, M., Hellman, U., and
Souchelnytskyi, S. (2004). Proteomics-based identification of proteins inter-
acting with Smad3: SREBP-2 forms a complex with Smad3 and inhibits its
transcriptional activity. FEBS Lett. 577, 93–100.
Gulen, M.F., Kang, Z., Bulek, K., Youzhong, W., Kim, T.W., Chen, Y., Altuntas,
C.Z., Sass Bak-Jensen, K., McGeachy, M.J., Do, J.S., et al. (2010). The recep-
tor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1
receptor pathway and mTOR kinase activation. Immunity 32, 54–66.
Guo, L.,Wei, G., Zhu, J., Liao,W., Leonard,W.J., Zhao, K., and Paul,W. (2009).
IL-1 family members and STAT activators induce cytokine production by Th2,
Th17, and Th1 cells. Proc. Natl. Acad. Sci. USA 106, 13463–13468.
Ho, J.E., Chen, W.Y., Chen, M.H., Larson, M.G., McCabe, E.L., Cheng, S.,
Ghorbani, A., Coglianese, E., Emilsson, V., Johnson, A.D., et al.;
CARDIoGRAM Consortium; CHARGE Inflammation Working Group; CHARGE
Heart Failure Working Group (2013). Common genetic variation at the IL1RL1
locus regulates IL-33/ST2 signaling. J. Clin. Invest. 123, 4208–4218.
Hoffman, H.M., Mueller, J.L., Broide, D.H.,Wanderer, A.A., and Kolodner, R.D.
(2001). Mutation of a new gene encoding a putative pyrin-like protein causes
familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat.
Genet. 29, 301–305.
Hong, D.S., Naing, A., Falchook, G.S., Piha-PAul, S., Wheler, J.J., Fu, S., Tsim-
beridou, A.M., Hui, D., Scott, R., Khan, R., et al. (2011). A phase I study of
MABp1, a first-in-human, first-true human monoclonal antibody against the
IL-1 in patients with advanced cancers. Mol. Cancer Ther. 10, A211.
Horai, R., Saijo, S., Tanioka, H., Nakae, S., Sudo, K., Okahara, A., Ikuse, T.,
Asano, M., and Iwakura, Y. (2000). Development of chronic inflammatory
arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antago-
nist-deficient mice. J. Exp. Med. 191, 313–320.
Huang, X., Hazlett, L.D., Du, W., and Barrett, R.P. (2006). SIGIRR promotes
resistance against Pseudomonas aeruginosa keratitis by down-regulating
type-1 immunity and IL-1R1 and TLR4 signaling. J. Immunol. 177, 548–556.
Hughes, T., Becknell, B., Freud, A.G., McClory, S., Briercheck, E., Yu, J., Mao,
C., Giovenzana, C., Nuovo, G., Wei, L., et al. (2010). Interleukin-1beta selec-
tively expands and sustains interleukin-22+ immature human natural killer cells
in secondary lymphoid tissue. Immunity 32, 803–814.
Ikutani, M., Yanagibashi, T., Ogasawara, M., Tsuneyama, K., Yamamoto, S.,
Hattori, Y., Kouro, T., Itakura, A., Nagai, Y., Takaki, S., and Takatsu, K.
(2012). Identification of innate IL-5-producing cells and their role in lung eosin-
ophil regulation and antitumor immunity. J. Immunol. 188, 703–713.1016 Immunity 39, December 12, 2013 ª2013 Elsevier Inc.Joeckel, L.T., Wallich, R., Metkar, S.S., Froelich, C.J., Simon, M.M., and
Borner, C. (2012). Interleukin-1R signaling is essential for induction of proapo-
ptotic CD8 T cells, viral clearance, and pathology during lymphocytic chorio-
meningitis virus infection in mice. J. Virol. 86, 8713–8719.
Kayagaki, N., Warming, S., Lamkanfi, M., Vande Walle, L., Louie, S., Dong, J.,
Newton, K., Qu, Y., Liu, J., Heldens, S., et al. (2011). Non-canonical inflamma-
some activation targets caspase-11. Nature 479, 117–121.
Kim, S.H., Eisenstein, M., Reznikov, L., Fantuzzi, G., Novick, D., Rubinstein,
M., and Dinarello, C.A. (2000). Structural requirements of six naturally occur-
ring isoforms of the IL-18 binding protein to inhibit IL-18. Proc. Natl. Acad.
Sci. USA 97, 1190–1195.
Krelin, Y., Voronov, E., Dotan, S., Elkabets, M., Reich, E., Fogel, M., Huszar,
M., Iwakura, Y., Segal, S., Dinarello, C.A., and Apte, R.N. (2007). Interleukin-
1beta-driven inflammation promotes the development and invasiveness of
chemical carcinogen-induced tumors. Cancer Res. 67, 1062–1071.
Kuhn, P.H., Marjaux, E., Imhof, A., De Strooper, B., Haass, C., and
Lichtenthaler, S.F. (2007). Regulated intramembrane proteolysis of the inter-
leukin-1 receptor II by alpha-, beta-, and gamma-secretase. J. Biol. Chem.
282, 11982–11995.
Kumar, S., Hanning, C.R., Brigham-Burke, M.R., Rieman, D.J., Lehr, R., Khan-
dekar, S., Kirkpatrick, R.B., Scott, G.F., Lee, J.C., Lynch, F.J., et al. (2002).
Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature
IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma produc-
tion. Cytokine 18, 61–71.
Kurowska-Stolarska, M., Stolarski, B., Kewin, P., Murphy, G., Corrigan, C.J.,
Ying, S., Pitman, N., Mirchandani, A., Rana, B., van Rooijen, N., et al. (2009).
IL-33 amplifies the polarization of alternatively activated macrophages that
contribute to airway inflammation. J. Immunol. 183, 6469–6477.
Langley, N.J. (1906). On nerve endings and on special excitable substances in
cells. Proc. R. Soc. Lond., B 78, 170.
Lech, M., Kulkarni, O.P., Pfeiffer, S., Savarese, E., Krug, A., Garlanda, C.,
Mantovani, A., and Anders, H.J. (2008). Tir8/Sigirr prevents murine lupus by
suppressing the immunostimulatory effects of lupus autoantigens. J. Exp.
Med. 205, 1879–1888.
Lech, M., Avila-Ferrufino, A., Allam, R., Segerer, S., Khandoga, A., Krombach,
F., Garlanda, C., Mantovani, A., and Anders, H.J. (2009). Resident dendritic
cells prevent postischemic acute renal failure by help of single Ig IL-1 recep-
tor-related protein. J. Immunol. 183, 4109–4118.
Lech,M., Skuginna, V., Kulkarni, O.P., Gong, J.,Wei, T., Stark, R.W., Garlanda,
C., Mantovani, A., and Anders, H.J. (2010). Lack of SIGIRR/TIR8 aggravates
hydrocarbon oil-induced lupus nephritis. J. Pathol. 220, 596–607.
Lefranc¸ais, E., Roga, S., Gautier, V., Gonzalez-de-Peredo, A., Monsarrat, B.,
Girard, J.P., and Cayrol, C. (2012). IL-33 is processed into mature bioactive
forms by neutrophil elastase and cathepsin G. Proc. Natl. Acad. Sci. USA
109, 1673–1678.
Liew, F.Y., Pitman, N.I., and McInnes, I.B. (2010). Disease-associated func-
tions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10, 103–110.
Liu, X., Hammel, M., He, Y., Tainer, J.A., Jeng, U.S., Zhang, L., Wang, S., and
Wang, X. (2013). Structural insights into the interaction of IL-33 with its recep-
tors. Proc. Natl. Acad. Sci. USA 110, 14918–14923.
Lorenzen, I., Lokau, J., Du¨sterho¨ft, S., Trad, A., Garbers, C., Scheller, J., Rose-
John, S., and Gro¨tzinger, J. (2012). The membrane-proximal domain of A
Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition
of the interleukin-6 receptor and interleukin-1 receptor II. FEBS Lett. 586,
1093–1100.
Luo, Y., Cai, X., Wang, S., Nold-Petry, C., Nold, M.F., Bulfer, P., Norris, D.,
Dinarello, C.A., and Fujita, M. (2013). IL-37 suppresses contact hypersensitiv-
ity by inducing tolerogenic dendritic cells. Cytokine 63, 283.
Maggi, L., Santarlasci, V., Capone, M., Rossi, M.C., Querci, V., Mazzoni, A.,
Cimaz, R., De Palma, R., Liotta, F., Maggi, E., et al. (2012). Distinctive features
of classic and nonclassic (Th17 derived) human Th1 cells. Eur. J. Immunol. 42,
3180–3188.
Mailliard, R.B., Alber, S.M., Shen, H., Watkins, S.C., Kirkwood, J.M., Herber-
man, R.B., and Kalinski, P. (2005). IL-18-induced CD83+CCR7+ NK helper
cells. J. Exp. Med. 202, 941–953.
Immunity
ReviewMaksymowych, W.P., Rahman, P., Reeve, J.P., Gladman, D.D., Peddle, L.,
and Inman, R.D. (2006). Association of the IL1 gene cluster with susceptibility
to ankylosing spondylitis: an analysis of three Canadian populations. Arthritis
Rheum. 54, 974–985.
Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related
inflammation. Nature 454, 436–444.
Mantovani, A., Cassatella, M.A., Costantini, C., and Jaillon, S. (2011). Neutro-
phils in the activation and regulation of innate and adaptive immunity. Nat. Rev.
Immunol. 11, 519–531.
Marrakchi, S., Guigue, P., Renshaw, B.R., Puel, A., Pei, X.Y., Fraitag, S., Zribi,
J., Bal, E., Cluzeau, C., Chrabieh, M., et al. (2011). Interleukin-36-receptor
antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med.
365, 620–628.
Martin, P., Palmer, G., Vigne, S., Lamacchia, C., Rodriguez, E., Talabot-Ayer,
D., Rose-John, S., Chalaris, A., and Gabay, C. (2013). Mouse neutrophils
express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in
acute inflammatory conditions. J. Leukoc. Biol. 94, 791–802.
McHedlidze, T., Waldner, M., Zopf, S., Walker, J., Rankin, A.L., Schuchmann,
M., Voehringer, D., McKenzie, A.N., Neurath, M.F., Pflanz, S., and Wirtz, S.
(2013). Interleukin-33-dependent innate lymphoid cells mediate hepatic
fibrosis. Immunity 39, 357–371.
McNamee, E.N., Masterson, J.C., Jedlicka, P., McManus, M., Grenz, A.,
Collins, C.B., Nold, M.F., Nold-Petry, C., Bufler, P., Dinarello, C.A., and
Rivera-Nieves, J. (2011). Interleukin 37 expression protects mice from colitis.
Proc. Natl. Acad. Sci. USA 108, 16711–16716.
Mercer, F., Kozhaya, L., and Unutmaz, D. (2010). Expression and function of
TNF and IL-1 receptors on human regulatory T cells. PLoS One 5, e8639.
Miller, A.M., Xu, D., Asquith, D.L., Denby, L., Li, Y., Sattar, N., Baker, A.H.,
McInnes, I.B., and Liew, F.Y. (2008). IL-33 reduces the development of athero-
sclerosis. J. Exp. Med. 205, 339–346.
Moffatt, M.F., Gut, I.G., Demenais, F., Strachan, D.P., Bouzigon, E., Heath, S.,
von Mutius, E., Farrall, M., Lathrop, M., and Cookson, W.O.; GABRIEL Con-
sortium (2010). A large-scale, consortium-based genomewide association
study of asthma. N. Engl. J. Med. 363, 1211–1221.
Molofsky, A.B., Nussbaum, J.C., Liang, H.E., Van Dyken, S.J., Cheng, L.E.,
Mohapatra, A., Chawla, A., and Locksley, R.M. (2013). Innate lymphoid type
2 cells sustain visceral adipose tissue eosinophils and alternatively activated
macrophages. J. Exp. Med. 210, 535–549.
Monteiro, M., Almeida, C.F., Agua-Doce, A., and Graca, L. (2013). Induced
IL-17-producing invariant NKT cells require activation in presence of TGF-b
and IL-1b. J. Immunol. 190, 805–811.
Moro, K., Yamada, T., Tanabe, M., Takeuchi, T., Ikawa, T., Kawamoto, H.,
Furusawa, J., Ohtani, M., Fujii, H., and Koyasu, S. (2010). Innate production
of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid
cells. Nature 463, 540–544.
Muzio, M., Ni, J., Feng, P., and Dixit, V.M. (1997). IRAK (Pelle) family member
IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278,
1612–1615.
Muzio, M., Natoli, G., Saccani, S., Levrero, M., and Mantovani, A. (1998). The
human toll signaling pathway: divergence of nuclear factor kappaB and JNK/
SAPK activation upstream of tumor necrosis factor receptor-associated factor
6 (TRAF6). J. Exp. Med. 187, 2097–2101.
Myles, I.A., Fontecilla, N.M., Valdez, P.A., Vithayathil, P.J., Naik, S., Belkaid,
Y., Ouyang, W., and Datta, S.K. (2013). Signaling via the IL-20 receptor inhibits
cutaneous production of IL-1b and IL-17A to promote infection with methi-
cillin-resistant Staphylococcus aureus. Nat. Immunol. 14, 804–811.
Neill, D.R., Wong, S.H., Bellosi, A., Flynn, R.J., Daly, M., Langford, T.K., Bucks,
C., Kane, C.M., Fallon, P.G., Pannell, R., et al. (2010). Nuocytes represent a
new innate effector leukocyte that mediates type-2 immunity. Nature 464,
1367–1370.
Netea, M.G., Joosten, L.A., Lewis, E., Jensen, D.R., Voshol, P.J., Kullberg,
B.J., Tack, C.J., van Krieken, H., Kim, S.H., Stalenhoef, A.F., et al. (2006). Defi-
ciency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resis-
tance. Nat. Med. 12, 650–656.Nicklin, M.J., Hughes, D.E., Barton, J.L., Ure, J.M., and Duff, G.W. (2000). Arte-
rial inflammation in mice lacking the interleukin 1 receptor antagonist gene.
J. Exp. Med. 191, 303–312.
Nold, M.F., Nold-Petry, C.A., Zepp, J.A., Palmer, B.E., Bufler, P., and Dinarello,
C.A. (2010). IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol.
11, 1014–1022.
Nold, M., Nold-Petry, C., Lo, C., Li, S., Zepp, J., Azam, T., Bulfer, P., Garlanda,
C., Mantovani, A., and Dinarello, C.A. (2013). Interleukin 37 employs the IL-1
family inhibitory receptor SIGIRR and the alpha chain of the IL-18 receptor
to suppress innate immunity. Cytokine 63, 287.
Nold-Petry, C.A., Nold, M.F., Nielsen, J.W., Bustamante, A., Zepp, J.A., Storm,
K.A., Hong, J.W., Kim, S.H., and Dinarello, C.A. (2009). Increased cytokine
production in interleukin-18 receptor alpha-deficient cells is associated with
dysregulation of suppressors of cytokine signaling. J. Biol. Chem. 284,
25900–25911.
Noris, M., Cassis, P., Azzollini, N., Cavinato, R., Cugini, D., Casiraghi, F., Aiello,
S., Solini, S., Cassis, L., Mister, M., et al. (2009). The Toll-IL-1R member Tir8/
SIGIRR negatively regulates adaptive immunity against kidney grafts.
J. Immunol. 183, 4249–4260.
Novick, D., Kim, S.H., Fantuzzi, G., Reznikov, L.L., Dinarello, C.A., and Rubin-
stein, M. (1999). Interleukin-18 binding protein: a novel modulator of the Th1
cytokine response. Immunity 10, 127–136.
Novick, D., Elbirt, D., Miller, G., Dinarello, C.A., Rubinstein, M., and Sthoeger,
Z.M. (2010). High circulating levels of free interleukin-18 in patients with active
SLE in the presence of elevated levels of interleukin-18 binding protein.
J. Autoimmun. 34, 121–126.
O’Shea, J.J., and Paul, W.E. (2010). Mechanisms underlying lineage commit-
ment and plasticity of helper CD4+ T cells. Science 327, 1098–1102.
Oboki, K., Ohno, T., Kajiwara, N., Arae, K., Morita, H., Ishii, A., Nambu, A., Abe,
T., Kiyonari, H., Matsumoto, K., et al. (2010). IL-33 is a crucial amplifier of
innate rather than acquired immunity. Proc. Natl. Acad. Sci. USA 107,
18581–18586.
Paget, C., Ivanov, S., Fontaine, J., Renneson, J., Blanc, F., Pichavant, M., Du-
moutier, L., Ryffel, B., Renauld, J.C., Gosset, P., et al. (2012). Interleukin-22 is
produced by invariant natural killer T lymphocytes during influenza A virus
infection: potential role in protection against lung epithelial damages. J. Biol.
Chem. 287, 8816–8829.
Palm, N.W., Rosenstein, R.K., Yu, S., Schenten, D.D., Florsheim, E., and
Medzhitov, R. (2013). Bee venom phospholipase A2 induces a primary type
2 response that is dependent on the receptor ST2 and confers protective
immunity. Immunity 39, 976–985.
Pecaric-Petkovic, T., Didichenko, S.A., Kaempfer, S., Spiegl, N., and
Dahinden, C.A. (2009). Human basophils and eosinophils are the direct target
leukocytes of the novel IL-1 family member IL-33. Blood 113, 1526–1534.
Pomerantz, B.J., Reznikov, L.L., Harken, A.H., and Dinarello, C.A. (2001).
Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via
inhibition of IL-18 and IL-1beta. Proc. Natl. Acad. Sci. USA 98, 2871–2876.
Puren, A.J., Fantuzzi, G., and Dinarello, C.A. (1999). Gene expression, synthe-
sis, and secretion of interleukin 18 and interleukin 1beta are differentially
regulated in human blood mononuclear cells and mouse spleen cells. Proc.
Natl. Acad. Sci. USA 96, 2256–2261.
Rahman, P., Sun, S., Peddle, L., Snelgrove, T., Melay, W., Greenwood, C., and
Gladman, D. (2006). Association between the interleukin-1 family gene cluster
and psoriatic arthritis. Arthritis Rheum. 54, 2321–2325.
Re, F., Sironi, M., Muzio, M., Matteucci, C., Introna, M., Orlando, S., Penton-
Rol, G., Dower, S.K., Sims, J.E., Colotta, F., and Mantovani, A. (1996). Inhibi-
tion of interleukin-1 responsiveness by type II receptor gene transfer: a surface
‘‘receptor’’ with anti-interleukin-1 function. J. Exp. Med. 183, 1841–1850.
Reddy, S., Jia, S., Geoffrey, R., Lorier, R., Suchi, M., Broeckel, U., Hessner,
M.J., and Verbsky, J. (2009). An autoinflammatory disease due to homozygous
deletion of the IL1RN locus. N. Engl. J. Med. 360, 2438–2444.
Rider, P., Carmi, Y., Guttman, O., Braiman, A., Cohen, I., Voronov, E., White,
M.R., Dinarello, C.A., and Apte, R.N. (2011). IL-1a and IL-1b recruit different
myeloid cells and promote different stages of sterile inflammation.
J. Immunol. 187, 4835–4843.Immunity 39, December 12, 2013 ª2013 Elsevier Inc. 1017
Immunity
ReviewRodrı´guez-Prados, J.C., Trave´s, P.G., Cuenca, J., Rico, D., Aragone´s, J., Mar-
tı´n-Sanz, P., Cascante, M., and Bosca´, L. (2010). Substrate fate in activated
macrophages: a comparison between innate, classic, and alternative activa-
tion. J. Immunol. 185, 605–614.
Russell, S.E., Stefanska, A.M., Kubica, M., Horan, R.M., Mantovani, A., Gar-
landa, C., Fallon, P.G., and Walsh, P.T. (2013). Toll IL-1R8/single Ig IL-1-
related receptor regulates psoriasiform inflammation through direct inhibition
of innate IL-17A expression by gd T cells. J. Immunol. 191, 3337–3346.
Sakai, N., Van Sweringen, H.L., Belizaire, R.M., Quillin, R.C., Schuster, R.,
Blanchard, J., Burns, J.M., Tevar, A.D., Edwards, M.J., and Lentsch, A.B.
(2012). Interleukin-37 reduces liver inflammatory injury via effects on hepato-
cytes and non-parenchymal cells. J. Gastroenterol. Hepatol. 27, 1609–1616.
Salcedo, R., Cataisson, C., Hasan, U., Yuspa, S.H., and Trinchieri, G. (2013).
MyD88 and its divergent toll in carcinogenesis. Trends Immunol. 34, 379–389.
Sanada, S., Hakuno, D., Higgins, L.J., Schreiter, E.R., McKenzie, A.N., and
Lee, R.T. (2007). IL-33 and ST2 comprise a critical biomechanically induced
and cardioprotective signaling system. J. Clin. Invest. 117, 1538–1549.
Santarlasci, V., Cosmi, L., Maggi, L., Liotta, F., and Annunziato, F. (2013). IL-1
and T helper immune responses. Front Immunol 4, 182, http://dx.doi.org/10.
3389/fimmu.2013.00182.
Sharma, S., Kulk, N., Nold, M.F., Gra¨f, R., Kim, S.H., Reinhardt, D., Dinarello,
C.A., and Bufler, P. (2008). The IL-1 family member 7b translocates to the
nucleus and down-regulates proinflammatory cytokines. J. Immunol. 180,
5477–5482.
Sica, A., Invernizzi, P., and Mantovani, A. (2013). Macrophage plasticity and
polarization in liver homeostasis and pathology. Hepatology, in press.
Siegmund, B., Fantuzzi, G., Rieder, F., Gamboni-Robertson, F., Lehr, H.A.,
Hartmann, G., Dinarello, C.A., Endres, S., and Eigler, A. (2001a). Neutralization
of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma
and TNF-alpha production. Am. J. Physiol. Regul. Integr. Comp. Physiol.
281, R1264–R1273.
Siegmund, B., Lehr, H.A., Fantuzzi, G., and Dinarello, C.A. (2001b). IL-1 beta
-converting enzyme (caspase-1) in intestinal inflammation. Proc. Natl. Acad.
Sci. USA 98, 13249–13254.
Sims, J.E., and Smith, D.E. (2010). The IL-1 family: regulators of immunity. Nat.
Rev. Immunol. 10, 89–102.
Smith, D.E., Hanna, R., Della Friend, Moore, H., Chen, H., Farese, A.M.,
MacVittie, T.J., Virca, G.D., and Sims, J.E. (2003). The soluble form of IL-1
receptor accessory protein enhances the ability of soluble type II IL-1 receptor
to inhibit IL-1 action. Immunity 18, 87–96.
Smith, D.E., Lipsky, B.P., Russell, C., Ketchem, R.R., Kirchner, J., Hensley, K.,
Huang, Y., Friedman, W.J., Boissonneault, V., Plante, M.M., et al. (2009). A
central nervous system-restricted isoform of the interleukin-1 receptor acces-
sory protein modulates neuronal responses to interleukin-1. Immunity 30,
817–831.
Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J.P., Eberl, G.,
Koyasu, S., Locksley, R.M., McKenzie, A.N., Mebius, R.E., et al. (2013). Innate
lymphoid cells—a proposal for uniform nomenclature. Nat. Rev. Immunol. 13,
145–149.
Sutton, C., Brereton, C., Keogh, B., Mills, K.H., and Lavelle, E.C. (2006). A
crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells
that mediate autoimmune encephalomyelitis. J. Exp. Med. 203, 1685–1691.
Tack, C.J., Stienstra, R., Joosten, L.A., and Netea, M.G. (2012). Inflammation
links excess fat to insulin resistance: the role of the interleukin-1 family. Immu-
nol. Rev. 249, 239–252.
Tannahill, G.M., Curtis, A.M., Adamik, J., Palsson-McDermott, E.M.,
McGettrick, A.F., Goel, G., Frezza, C., Bernard, N.J., Kelly, B., Foley, N.H.,
et al. (2013). Succinate is an inflammatory signal that induces IL-1b through
HIF-1a. Nature 496, 238–242.
Tjota, M.Y., Williams, J.W., Lu, T., Clay, B.S., Byrd, T., Hrusch, C.L., Decker,
D.C., de Araujo, C.A., Bryce, P.J., and Sperling, A.I. (2013). IL-33-dependent
induction of allergic lung inflammation by FcgRIII signaling. J. Clin. Invest.
123, 2287–2297.
Tortola, L., Rosenwald, E., Abel, B., Blumberg, H., Scha¨fer, M., Coyle, A.J.,
Renauld, J.C., Werner, S., Kisielow, J., and Kopf, M. (2012). Psoriasiform1018 Immunity 39, December 12, 2013 ª2013 Elsevier Inc.dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J. Clin.
Invest. 122, 3965–3976.
Towne, J.E., Renshaw, B.R., Douangpanya, J., Lipsky, B.P., Shen, M., Gabel,
C.A., and Sims, J.E. (2011). Interleukin-36 (IL-36) ligands require processing
for full agonist (IL-36a, IL-36b, and IL-36g) or antagonist (IL-36Ra) activity.
J. Biol. Chem. 286, 42594–42602.
van de Veerdonk, F.L., Stoeckman, A.K., Wu, G., Boeckermann, A.N., Azam,
T., Netea, M.G., Joosten, L.A., van der Meer, J.W., Hao, R., Kalabokis, V.,
and Dinarello, C.A. (2012). IL-38 binds to the IL-36 receptor and has biological
effects on immune cells similar to IL-36 receptor antagonist. Proc. Natl. Acad.
Sci. USA 109, 3001–3005.
van der Meer, J.W., Barza, M., Wolff, S.M., and Dinarello, C.A. (1988). A low
dose of recombinant interleukin 1 protects granulocytopenic mice from lethal
gram-negative infection. Proc. Natl. Acad. Sci. USA 85, 1620–1623.
Vander Lugt, M.T., Braun, T.M., Hanash, S., Ritz, J., Ho, V.T., Antin, J.H.,
Zhang, Q., Wong, C.H., Wang, H., Chin, A., et al. (2013). ST2 as a marker for
risk of therapy-resistant graft-versus-host disease and death. N. Engl. J.
Med. 369, 529–539.
Veldhoen, M., Hocking, R.J., Atkins, C.J., Locksley, R.M., and Stockinger, B.
(2006). TGFbeta in the context of an inflammatory cytokine milieu supports de
novo differentiation of IL-17-producing T cells. Immunity 24, 179–189.
Vigne, S., Palmer, G., Lamacchia, C., Martin, P., Talabot-Ayer, D., Rodriguez,
E., Ronchi, F., Sallusto, F., Dinh, H., Sims, J.E., and Gabay, C. (2011). IL-36R
ligands are potent regulators of dendritic and T cells. Blood 118, 5813–5823.
Vigne, S., Palmer, G., Martin, P., Lamacchia, C., Strebel, D., Rodriguez, E.,
Olleros, M.L., Vesin, D., Garcia, I., Ronchi, F., et al. (2012). IL-36 signaling
amplifies Th1 responses by enhancing proliferation and Th1 polarization of
naive CD4+ T cells. Blood 120, 3478–3487.
Wald, D., Qin, J., Zhao, Z., Qian, Y., Naramura, M., Tian, L., Towne, J., Sims,
J.E., Stark, G.R., and Li, X. (2003). SIGIRR, a negative regulator of Toll-like
receptor-interleukin 1 receptor signaling. Nat. Immunol. 4, 920–927.
Wang, D., Zhang, S., Li, L., Liu, X., Mei, K., and Wang, X. (2010). Structural
insights into the assembly and activation of IL-1b with its receptors. Nat.
Immunol. 11, 905–911.
Xiao, H., Gulen, M.F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C.Z., Wald,
D., Ma, C., Zhou, H., et al. (2007). The Toll-interleukin-1 receptor member
SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumori-
genesis. Immunity 26, 461–475.
Xiao, H., Yin, W., Khan, M.A., Gulen, M.F., Zhou, H., Sham, H.P., Jacobson, K.,
Vallance, B.A., and Li, X. (2010). Loss of single immunoglobulin interlukin-1
receptor-related molecule leads to enhanced colonic polyposis in Apc(min)
mice. Gastroenterology 139, 574–585.
Yousif, N.G., Li, J., Yousif, F., Ao, L., Nold, M.F., Nold-Petry, C., Fullerton, D.A.,
Dinarello, C.A., and Meng, X. (2011). Expression of IL-37 in mouse protects
the myocardium against ischemic injury via modulation of NF-kB activation.
Circulation 124 (Suppl 21 ), A8603.
Zaiss, M.M., Maslowski, K.M., Mosconi, I., Guenat, N., Marsland, B.J., and
Harris, N.L. (2013). IL-1b suppresses innate IL-25 and IL-33 production and
maintains helminth chronicity. PLoS Pathog. 9, e1003531.
Zeng, X., Wei, Y.L., Huang, J., Newell, E.W., Yu, H., Kidd, B.A., Kuhns, M.S.,
Waters, R.W., Davis, M.M., Weaver, C.T., and Chien, Y.H. (2012). gd T cells
recognize amicrobial encoded B cell antigen to initiate a rapid antigen-specific
interleukin-17 response. Immunity 37, 524–534.
Zhao, J., Wei, J., Mialki, R.K., Mallampalli, D.F., Chen, B.B., Coon, T., Zou, C.,
Mallampalli, R.K., and Zhao, Y. (2012). F-box protein FBXL19-mediated
ubiquitination and degradation of the receptor for IL-33 limits pulmonary
inflammation. Nat. Immunol. 13, 651–658.
Zheng, Y., Humphry, M., Maguire, J.J., Bennett, M.R., and Clarke, M.C. (2013).
Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of
interleukin-1a, controlling necrosis-induced sterile inflammation. Immunity 38,
285–295.
Zielinski, C.E., Mele, F., Aschenbrenner, D., Jarrossay, D., Ronchi, F.,
Gattorno, M., Monticelli, S., Lanzavecchia, A., and Sallusto, F. (2012). Path-
ogen-induced human TH17 cells produce IFN-g or IL-10 and are regulated
by IL-1b. Nature 484, 514–518.
